### Meta-analysis fine-mapping is often miscalibrated at single-variant resolution

Masahiro Kanai<sup>1,2,3,4,5,\*</sup>, Roy Elzur<sup>1,2,3</sup>, Wei Zhou<sup>1,2,3</sup>, Global Biobank Meta-analysis Initiative, Mark J Daly<sup>1,2,3,6</sup>, Hilary K Finucane<sup>1,2,3,\*</sup>

<sup>1</sup>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA, <sup>2</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, <sup>3</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA, <sup>4</sup>Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA, <sup>5</sup>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan, <sup>6</sup>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

\* Corresponding authors: Masahiro Kanai (<u>mkanai@broadinstitute.org</u>) and Hilary K Finucane (<u>finucane@broadinstitute.org</u>)

## Abstract

Meta-analysis is pervasively used to combine multiple genome-wide association studies (GWAS) into a more powerful whole. To resolve causal variants, meta-analysis studies typically apply summary statistics-based fine-mapping methods as they are applied to single-cohort studies. However, it is unclear whether heterogeneous characteristics of each cohort (e.g., ancestry, sample size, phenotyping, genotyping, or imputation) affect fine-mapping calibration and recall. Here, we first demonstrate that meta-analysis fine-mapping is substantially miscalibrated in simulations when different genotyping arrays or imputation panels are included. To mitigate these issues, we propose a summary statistics-based QC method, SLALOM, that identifies suspicious loci for meta-analysis fine-mapping by detecting outliers in association statistics based on ancestry-matched local LD structure. Having validated SLALOM performance in simulations and the GWAS Catalog, we applied it to 14 disease endpoints from the Global Biobank Meta-analysis Initiative and found that 67% of loci showed suspicious patterns that call into question finemapping accuracy. These predicted suspicious loci were significantly depleted for having likely causal variants, such as nonsynonymous variants, as a lead variant (2.7x; Fisher's exact P = 7.3 $\times$  10<sup>-4</sup>). Compared to fine-mapping results in individual biobanks, we found limited evidence of fine-mapping improvement in the GBMI meta-analyses. Although a full solution requires complete synchronization across cohorts, our approach identifies likely spurious results in meta-analysis fine-mapping. We urge extreme caution when interpreting fine-mapping results from metaanalysis.

## 1 Introduction

2 Meta-analysis is pervasively used to combine multiple genome-wide association studies (GWAS) 3 from different cohorts<sup>1</sup>. Previous GWAS meta-analyses have identified thousands of loci 4 associated with complex diseases and traits, such as type 2 diabetes<sup>2,3</sup>, schizophrenia<sup>4,5</sup>, rheumatoid arthritis<sup>6,7</sup>, body mass index<sup>8</sup>, and lipid levels<sup>9</sup>. These meta-analyses are typically 5 6 conducted in large-scale consortia (e.g., the Psychiatric Genomics Consortium [PGC], the Global 7 Lipids Genetics Consortium [GLGC], and the Genetic Investigation of Anthropometric Traits 8 [GIANT] consortium) to increase sample size while harmonizing analysis plans across 9 participating cohorts in every possible aspect (e.g., phenotype definition, quality-control [QC] 10 criteria, statistical model, and analytical software) by sharing summary statistics as opposed to 11 individual-level data, thereby avoiding data protection issues and variable legal frameworks 12 governing individual genome and medical data around the world. The Global Biobank Metaanalysis Initiative (GBMI)<sup>10</sup> is one such large-scale, international effort, which aims to establish a 13 14 collaborative network spanning 23 biobanks from four continents (total n = 2.2 million) for 15 coordinated GWAS meta-analyses, while addressing the many benefits and challenges in meta-16 analysis and subsequent downstream analyses.

17

18 One such challenging downstream analysis is statistical fine-mapping<sup>11–13</sup>. Despite the great 19 success of past GWAS meta-analyses in locus discovery, individual causal variants in associated 20 loci are largely unresolved. Identifying causal variants from GWAS associations (i.e., fine-21 mapping) is challenging due to extensive linkage disequilibrium (LD, the correlation among 22 genetic variants), the presence of multiple causal variants, and limited sample sizes, but is rapidly becoming achievable with high confidence in individual cohorts<sup>14–17</sup> owing to the recent 23 development of large-scale biobanks<sup>18-20</sup> and scalable fine-mapping methods<sup>21-23</sup> that enable 24 25 well-powered, accurate fine-mapping using in-sample LD from large-scale individual-level data.

26

After conducting GWAS meta-analysis, previous studies<sup>2,7,9,24-30</sup> have applied existing summary 27 statistics-based fine-mapping methods (e.g., approximate Bayes factor [ABF]<sup>31,32</sup>, CAVIAR<sup>33</sup>, 28 PAINTOR<sup>34,35</sup>, FINEMAP<sup>21,22</sup>, and SuSiE<sup>23</sup>) just as they are applied to single-cohort studies, 29 30 without considering or accounting for the unavoidable heterogeneity among cohorts (e.g. 31 differences in sample size, phenotyping, genotyping, or imputation). Such heterogeneity could 32 lead to false positives and miscalibration in meta-analysis fine-mapping (Fig. 1). For example, 33 case-control studies enriched with more severe cases or ascertained with different phenotyping 34 criteria may disproportionately contribute to genetic discovery, even when true causal effects for 35 genetic liability are exactly the same between these studies and less severe or unascertained 36 ones. Quantitative traits like biomarkers could have phenotypic heterogeneity arising from 37 different measurement protocols and errors across studies. There might be genuine biological mechanisms too, such as gene-gene (GxG) and gene-environment (GxE) interactions and 38 39 (population-specific) dominance variation (e.g., rs671 and alcohol dependence<sup>36</sup>), that introduce additional heterogeneity across studies<sup>37,38</sup>. In addition to phenotyping, differences in genotyping 40 41 and imputation could dramatically undermine fine-mapping calibration and recall at single-variant 42 resolution, because differential patterns of missingness and imputation quality across constituent 43 cohorts of different sample sizes can disproportionately diminish association statistics of 44 potentially causal variants. Finally, although more easily harmonized than phenotyping and 45 genotyping data, subtle differences in QC criteria and analytical software may further exacerbate 46 the effect of heterogeneity on fine-mapping.

47

An illustrative example of such issues can be observed in the *TYK2* locus (19p13.2) in the recent meta-analysis from the COVID-19 Host Genetics Initiative (COVID-19 HGI; **Fig. S1**)<sup>39</sup>. This locus is known for protective associations against autoimmune diseases<sup>6,24</sup>, while a complete *TYK2* 

loss of function results in a primary immunodeficiency<sup>40</sup>. Despite strong LD ( $r^2 = 0.82$ ) with a lead 51 variant in the locus (rs74956615;  $P = 9.7 \times 10^{-12}$ ), a known functional missense variant 52 rs34536443 (p.Pro1104Ala) that reduces TYK2 function<sup>41,42</sup> did not achieve genome-wide 53 54 significance and was assigned a very low PIP in fine-mapping ( $P = 7.5 \times 10^{-7}$ ; PIP =  $9.5 \times 10^{-4}$ ), 55 primarily due to its missingness in two more cohorts than rs74956615. This serves as just one 56 example of the major difficulties with meta-analysis fine-mapping at single-variant resolution. 57 Indeed, the COVID-19 HGI cautiously avoided an *in-silico* fine-mapping in the flagship to prevent 58 spurious results<sup>39</sup>.

59

60 Only a few studies have carefully addressed these concerns in their downstream analyses. The Schizophrenia Working Group of PGC, for example, recently updated their largest meta-analysis 61 62 of schizophrenia<sup>5</sup> (69,369 cases and 236,642 controls), followed by a downstream fine-mapping 63 analysis using FINEMAP<sup>21</sup>. Unlike many other GWAS consortia, since PGC has access to individual-level genotypes for a majority of samples, they were able to apply standardized sample 64 65 and variant QC criteria and impute variants using the same reference panel, all uniformly processed using the RICOPILI pipeline<sup>43</sup>. This harmonized procedure was crucial for properly 66 67 controlling inter-cohort heterogeneity and thus allowing more robust meta-analysis fine-mapping 68 at single-variant resolution. Furthermore, PGC's direct access to individual-level data enabled 69 them to compute in-sample LD matrices for multiple causal variant fine-mapping, which prevents the significant miscalibration that results from using an external LD reference<sup>14-16</sup>. A 2017 fine-70 71 mapping study of inflammatory bowel disease also benefited from access to individual-level genotypes and careful pre- and post-fine-mapping QC<sup>44</sup>. For a typical meta-analysis consortium, 72 73 however, many of these steps are infeasible as full genotype data from all cohorts is not available. 74 For such studies, a new approach to meta-analysis fine-mapping in the presence of the many 75 types of heterogeneity is needed. Until such a method is developed. QC of meta-analysis fine-76 mapping results deserves increased attention.

77

78 While existing variant-level QC procedures are effective for limiting spurious associations in GWAS (**Supplementary Box**)<sup>45</sup>, they do not suffice for ensuring high-quality fine-mapping results. 79 In some cases, they even hurt fine-mapping quality, because they can i) cause or exacerbate 80 81 differential patterns of missing variants across cohorts, and ii) remove true causal variants as well 82 as suspicious variants. Thus, additional QC procedures that retain consistent variants across 83 cohorts for consideration but limit poor-quality fine-mapping results are needed. A recently proposed method called DENTIST<sup>46</sup>, for example, performs summary statistics QC to improve 84 GWAS downstream analyses, such as conditional and joint analysis (GCTA-COJO<sup>47</sup>), by 85 86 removing variants based on estimated heterogeneity between summary statistics and reference LD. Although DENTIST was also applied prior to fine-mapping (FINEMAP<sup>21</sup>), simulations only 87 demonstrated that it could improve power for detecting the correct number of causal variants in a 88 89 locus, not true causal variants. This motivated us to develop a new fine-mapping QC method for 90 better calibration and recall at single-variant resolution and to demonstrate its performance in 91 large-scale meta-analysis.

92

Here, we first demonstrate the effect of inter-cohort heterogeneity in meta-analysis fine-mapping 93 94 via realistic simulations with multiple heterogeneous cohorts, each with different combinations of 95 genotyping platforms, imputation reference panels, and genetic ancestries. We propose a summary statistics-based QC method, SLALOM (suspicious loci analysis of meta-analysis 96 97 summary statistics), that identifies suspicious loci for meta-analysis fine-mapping by detecting association statistics outliers based on local LD structure, building on the DENTIST method. 98 99 Applying SLALOM to 14 disease endpoints from the Global Biobank Meta-analysis Initiative<sup>10</sup> as 100 well as 467 meta-analysis summary statistics from the GWAS Catalog<sup>48</sup>, we demonstrate that

- 101 suspicious loci for fine-mapping are widespread in meta-analysis and urge extreme caution when
- 102 interpreting fine-mapping results from meta-analysis.
- 103



104 105

IO5 Fig. 1 | Schematic overview of meta-analysis fine-mapping.

106 Results

## 107 Large-scale simulations demonstrate miscalibration in meta-analysis fine-mapping

Existing fine-mapping methods<sup>21,23,31</sup> assume that all association statistics are derived from a 108 single-cohort study, and thus do not model the per-variant heterogeneity in effect sizes and 109 sample sizes that arise when meta-analyzing multiple cohorts (Figure 1). To evaluate how 110 111 different characteristics of constituent cohorts in a meta-analysis affect fine-mapping calibration 112 and recall, we conducted a series of large-scale GWAS meta-analysis and fine-mapping simulations (Table S1-4; Methods). Briefly, we simulated multiple GWAS cohorts of different 113 114 ancestries (10 European ancestry, one African ancestry and one East Asian ancestry cohorts; n 115 = 10,000 each) that were genotyped and imputed using different genotyping arrays (Illumina 116 Omni2.5, Multi-Ethnic Global Array [MEGA], and Global Screening Array [GSA]) and imputation reference panels (the 1000 Genomes Project Phase 3 [1000GP3]<sup>49</sup>, the Haplotype Reference 117 Consortium [HRC]<sup>50</sup>, and the TOPMed<sup>51</sup>). For each combination of cohort, genotyping array, and 118 119 imputation panel, we conducted 300 GWAS with randomly simulated causal variants that 120 resemble the genetic architecture of a typical complex trait, including minor allele frequency (MAF) dependent causal effect sizes<sup>52</sup>, total SNP heritability<sup>53</sup>, functional consequences of causal 121 122 variants<sup>17</sup>, and levels of genetic correlation across cohorts (*i.e.*, true effect size heterogeneity;  $r_{\rm q}$ 123 = 1, 0.9, and 0.5; see **Methods**). We then meta-analyzed the single-cohort GWAS results across 124 10 independent cohorts based on multiple *configurations* (different combinations of genotyping 125 arrays and imputation panels for each cohort) to resemble realistic meta-analysis of multiple 126 heterogeneous cohorts (Table S4). We applied ABF fine-mapping to compute a posterior 127 inclusion probability (PIP) for each variant and to derive 95% and 99% credible sets (CS) that 128 contain the smallest set of variants covering 95% and 99% of probability of causality. We 129 evaluated the false discovery rate (FDR, defined as the proportion of variants with PIP > 0.9 that 130 are non-causal) and compared against the expected proportion of non-causal variants if the meta-131 analysis fine-mapping method were calibrated, based on PIP. More details of our simulation 132 pipeline are described in Methods and visually summarized in Fig. S2.

#### 133

134 We found that FDR varied widely over the different configurations, reaching as high as 37% for the most heterogeneous configurations (Fig. 2). We characterized the contributing factors to the 135 136 miscalibration. We first found that lower true effect size correlation  $r_{g}$  (*i.e.*, larger phenotypic 137 heterogeneity) always caused higher miscalibration and lower recall. Second, when using the 138 same imputation panel (1000GP3), use of less dense arrays (MEGA or GSA) led to moderately 139 inflated FDR (up to FDR = 11% vs. expected 1%), while use of multiple genotyping array did not 140 cause further FDR inflation (Fig. 2a). Third, when using the same genotyping array (Omni2.5), 141 use of imputation panels (HRC or TOPMed) that does not match our simulation reference 142 significantly affects miscalibration (up to FDR = 17% vs. expected 1%), and using multiple 143 imputation panels further increased miscalibration (up to FDR = 35% vs. expected 2%, Fig. 2c): 144 this setup is as bad as the most heterogeneous configuration using multiple genotyping arrays 145 and imputation panels (FDR = 37%). When TOPMed-imputed variants were lifted over from 146 GRCh38 to GRCh37, we observed FDR increases of up to 10%, likely due to genomic build conversion failures (Supplementary Note)<sup>54</sup>. Fourth, recall was not significantly affected by 147 148 heterogeneous genotyping arrays or imputation panels (Fig. 2b,d). Fifth, including multiple 149 genetic ancestries did not affect calibration when using the same genotyping array and imputation 150 panel (Omni 2.5 and 1000GP3; Fig. 2e) but significantly improved recall if African ancestry was included (Fig. 2f). This is expected, given the shorter LD length in the African population 151 152 compared to other populations, which improves fine-mapping resolution<sup>55</sup>. Finally, in the most 153 heterogeneous configurations where multiple genotyping arrays and imputation panels existed. 154 we observed a FDR of up to 37% and 28% for European and multi-ancestry meta-analyses, 155 respectively (vs. expected 2% for both), demonstrating that inter-cohort heterogeneity can 156 substantially undermine meta-analysis fine-mapping (Fig. 2g,h).

157

158 To further characterize observed miscalibration in meta-analysis fine-mapping, we investigated 159 the availability of GWAS variants in each combination of ancestry, genotyping array, and 160 imputation panel. Out of 3,285,617 variants on chromosome 3 that passed variant QC in at least 161 one combination (per-combination MAF > 0.001 and Rsq > 0.6; Methods), 574,261 variants 162 (17%) showed population-level gnomAD MAF > 0.001 in every ancestry that we simulated 163 (African, East Asian, and European). Because we used a variety of imputation panels, we 164 retrieved population-level MAF from gnomAD. Of these 574,261 variants, 389,219 variants (68%) 165 were available in every combination (Fig. S3a). This fraction increased from 68% to 73%, 74%, 166 and 76% as we increased gnomAD MAF thresholds to > 0.005, 0.01, and 0.05, respectively, but 167 never reached 100% (Fig. S4). Notably, we observed a substantial number of variants that are 168 unique to a certain genotyping array and an imputation panel, even when we restricted to 344,497 169 common variants (gnomAD MAF > 0.05) in every ancestry (Fig. S3b). For example, there are 170 34.317 variants (10%) that were imputed in the 1000GP3 and TOPMed reference but not in the 171 HRC. Likewise, we observed 33,106 variants (10%) that were specific to the 1000GP3 reference 172 and even 3,066 variants (1%) that were imputed in every combination except for East Asian 173 ancestry with the GSA array and the TOPMed reference. When using different combinations of 174 gnomAD MAF thresholds (> 0.001, 0.005, 0.01, or 0.05 in every ancestry) and Rsq thresholds (> 175 0.2, 0.4, 0.6, or 0.8), we observed the largest fraction of shared variants (78%) was achieved with 176 gnomAD MAF > 0.01 and Rsg > 0.2 while the largest number of the shared variants (427.494 177 variants) was achieved with gnomAD MAF > 0.001 and Rsg > 0.2, leaving it unclear which 178 thresholds would be preferable in the context of fine-mapping (Fig. S4).

179

The remaining 2,711,356 QC-passing variants in our simulations (gnomAD MAF  $\leq$  0.001 in at least one ancestry) further exacerbate variable coverage of the available variants (**Fig. S3c**). Of these, the largest proportion of variants (39%) were only available in African ancestry, followed

183 by African and European (but not in East Asian) available variants (7%), European-specific 184 variants (6%), and East Asian-specific variants (5%). Furthermore, similar to the aforementioned 185 common variants, we found a substantial number of variants that are unique to a certain 186 combination. Altogether, we observed that only 393,471 variants (12%) out of all the QC-passing 187 3.285.617 variants were available in every combination (Fig. S3d). These observations 188 recapitulate that different combinations of genetic ancestry, genotyping array, imputation panels, 189 and QC thresholds substantially affect the availability of common, well-imputed variants for 190 association testing<sup>56</sup>.

191

192 Thus, the different combinations of genotyping and imputation cause each cohort in a meta-193 analysis to have a different set of variants, and consequently variants can have very different 194 overall sample sizes. In our simulations with the most heterogeneous configurations, we found 195 that 66% of the false positive loci (where a non-causal [false positive] variant was assigned PIP 196 > 0.9) had different sample sizes for true causal and false positive variants (median 197 maximum/minimum sample size ratio = 1.4; Fig. S5). Analytically, we found that at common meta-198 analysis sample sizes and genome-wide significant effect size regimes, when two variants have 199 similar marginal effects, the one with the larger sample size will usually achieve a higher ABF PIP 200 (Supplementary Note; Fig. S6-8). This elucidates the mechanism by which sample size 201 imbalance can lead to miscalibration.

202



204Genotyping arrayImputation panelGenetic ancestryHeterogenous settings205Fig. 2 | Evaluation of false discovery rate (FDR) and recall in meta-analysis fine-mapping simulations. Weevaluated FDR and recall in meta-analysis fine-mapping using different genotyping arrays (a,b), imputation reference207panels (c,d), genetic ancestries (e, f), and more heterogeneous settings by combining these (g, h). As shown in top-208right gray labels, the EUR ancestry, the Omni2.5 genotyping array and/or the 1000GP3 reference panel were used209unless otherwise stated. FDR is defined as the proportion of non-causal variants with PIP > 0.9. Horizontal gray lines210represent 1 – mean PIP, *i.e.* expected FDR were the method calibrated. Recall is defined as the proportion of true211causal variants in the top 1% PIP bin. Shapes correspond to the true effect size correlation  $r_g$  across cohorts which212represent a phenotypic heterogeneity parameter (the lower  $r_g$ , the higher phenotypic heterogeneity).

#### 213 Overview of the SLALOM method

To address the challenges in meta-analysis fine-mapping discussed above, we developed SLALOM (<u>suspicious loci analysis of meta-analysis summary statistics</u>), a method that flags suspicious loci for meta-analysis fine-mapping by detecting outliers in association statistics based on deviations from expectation, estimated with local LD structure (**Methods**). SLALOM consists of three steps, 1) defining loci and lead variants based on a 1 Mb window, 2) detecting outlier variants in each locus using meta-analysis summary statistics and an external LD reference panel, and 3) identifying suspicious loci for meta-analysis fine-mapping (**Fig. 3a,b**).

221

To detect outlier variants, we first assume a single causal variant per associated locus. Then the marginal z-score  $z_i$  for a variant *i* should be approximately equal to  $r_{i,c} \cdot z_c$  where  $z_c$  is the z-score of the causal variant *c*, and  $r_{i,c}$  is a correlation between variants *i* and *c*. For each variant in metaanalysis summary statistics, we first test this relationship using a simplified version of the DENTIST statistics<sup>46</sup>, DENTIST-S, based on the assumption of a single causal variant. The DENTIST-S statistics for a given variant *i* is written as

228

229  $T_i = \frac{(z_i - r_{i,c} \cdot z_c)^2}{1 - r_{i,c}^2}$ (1) 230

which approximately follows a  $\chi^2$  distribution with 1 degree of freedom<sup>46</sup>. Since the true causal variant and LD structure are unknown in real data, we approximate the causal variant as the lead PIP variant in the locus (the variant with the highest PIP) and use a large-scale external LD reference from gnomAD<sup>57</sup>, either an ancestry-matched LD for a single-ancestry meta-analysis or a sample-size-weighted LD by ancestries for a multi-ancestry meta-analysis (**Methods**). We note that the existence of multiple independent causal variants in a locus would not affect SLALOM precision but would decrease recall (see **Discussion**).

238 239 SLALOM then evaluates whether each locus is "suspicious"—that is, has a pattern of meta-240 analysis statistics and LD that appear inconsistent and therefore call into question the fine-241 mapping accuracy. By training on loci with maximum PIP > 0.9 in the simulations, we determined that the best-performing criterion for classifying loci as true or false positives is whether a locus 242 has a variant with  $r^2 > 0.6$  to the lead and DENTIST-S *P*-value  $< 1.0 \times 10^{-4}$  (Methods). Using this 243 244 criterion we achieved an area under the receiver operating characteristic curve (AUROC) of 0.74. 245 0.76, and 0.80 for identifying whether a true causal variant is a lead PIP variant, in 95% credible 246 set (CS), and in 99% CS, respectively (Fig. 3c). Using different thresholds, we observed that the 247 SLALOM performance is not very sensitive to thresholds near the threshold we chose (Fig. S9). 248 We further validated the performance of SLALOM using all the loci in the simulations and 249 observed significantly higher miscalibration in predicted suspicious loci than in non-suspicious 250 loci (up to 16% difference in FDR at PIP > 0.9; Fig. 3d). We found that SLALOM-predicted 251 "suspicious" loci tend to be from more heterogeneous configurations and the SLALOM sensitivity 252 and specificity depends on the level of heterogeneity (Table S5). Given the relatively lower 253 miscalibration and specificity at low PIP thresholds (Fig. 3d,e), in subsequent real data analysis 254 we restricted the application of SLALOM to loci with maximum PIP > 0.1 (Methods).





Fig. 3 | Overview of the SLALOM method. a,b. An illustrative example of the SLALOM application. a. In an example locus, two independent association signals are depicted: i) the most significant signal that contains a lead variant (purple diamond) and five additional variants that are in strong LD ( $r^2 > 0.9$ ) with the lead variant, and ii) an additional independent signal ( $r^2 < 0.05$ ). There is one outlier variant (orange diamond) in the first signal that deviates from the expected association based on LD. b. Step-by-step procedure of the SLALOM method. For outlier variant detection in a locus, a diagnosis plot of  $r^2$  values to the lead variant vs. marginal  $\chi^2$  is shown to aid interpretation. Background color represents a theoretical distribution of  $-\log_{10} P_{\text{DENTIST-S}}$  values when a lead variant has a marginal  $\chi^2$  of 50, assuming no allele flipping. Points represent the variants depicted in the example locus (a), where the lead variant (purple diamond) and the outlier variant (white diamond) were highlighted. Diagonal line represents an expected marginal association. Horizontal dotted lines represent the genome-wide significance threshold ( $P < 5.0 \times 10^{-8}$ ). c. The ROC curve of SLALOM prediction for identifying suspicious loci in the simulations. Positive conditions were defined as whether a true causal variant in a locus is 1) a lead PIP variant, 2) in 95% CS, and 3) in 99% CS. AUROC values were shown in the labels. Black points represent the performance of our adopted metric, *i.e.*, whether a locus contains at least one outlier variant ( $P_{\text{DENTIST-S}} < 1.0 \times 10^{-4}$  and  $r^2 > 0.6$ ). **d**. Calibration plot in the simulations under different PIP thresholds. Calibration was measured as the mean PIP - fraction of true causal variants among variants above the threshold. Shadows around the lines represent 95% confidence intervals. e. The fraction of variants in predicted suspicious and non-suspicious loci under different PIP thresholds. Gray shadows in the panels d,e represent a PIP ≤ 274 0.1 region as we excluded loci with maximum PIP  $\leq$  0.1 in the actual SLALOM analysis based on these panels.

# Widespread suspicious loci for fine-mapping in existing meta-analysis summary statistics

278 Having assessed the performance of SLALOM in simulations, we applied SLALOM to 467 metaanalysis summary statistics in the GWAS Catalog<sup>48</sup> that are publicly available with a sufficient 279 280 discovery sample size (N > 10,000; Table S6; Methods) to quantify the prevalence of suspicious 281 loci in existing studies. These summary statistics were mostly European ancestry-only metaanalysis (63%), followed by multi-ancestry (31%), East Asian ancestry-only (3%), and African 282 283 ancestry-only (2%) meta-analyses. Across 467 summary statistics from 96 publications, we identified 28,925 loci with maximum PIP > 0.1 (out of 35,864 genome-wide significant loci defined 284 285 based on 1 Mb window around lead variants; Methods) for SLALOM analysis, of which 8,137 loci 286 (28%) were predicted suspicious (Table S7).

287

288 To validate SLALOM performance in real data, we restricted our analysis to 6,065 loci that have maximum PIP > 0.1 and that contain nonsynonymous coding variants (predicted loss-of-function 289 [pLoF] and missense) in LD with the lead variant ( $r^2 > 0.6$ ). Given prior evidence<sup>16,17,44</sup> that such 290 291 nonsynonymous variants are highly enriched for being causal, we tested the validity of our method 292 by whether they achieve the highest PIP in the locus (*i.e.*, successful fine-mapping) in suspicious 293 vs. non-suspicious loci (Methods). While 40% (1,557 / 3,860) of non-suspicious loci successfully 294 fine-mapped nonsynonymous variants, only 17% (384 / 2,205) of suspicious loci did, 295 demonstrating a significant depletion (2.3x) of successfully fine-mapped nonsynonymous variants in suspicious loci (Fisher's exact  $P = 3.6 \times 10^{-79}$ ; Fig. 4a). We also tested whether 296 297 nonsynonymous variants belonged to 95% and 99% CS and again observed significant depletion 298 (1.4x and 1.3x, respectively; Fisher's exact  $P < 4.6 \times 10^{-100}$ ). In addition, when we used a more 299 stringent  $r^2$  threshold (> 0.8) for selecting loci that contain nonsynonymous variants, we also confirmed significant enrichment (Fisher's exact  $P < 6.1 \times 10^{-65}$ ; Fig. S10). To quantify potential 300 301 fine-mapping miscalibration in the GWAS Catalog, we investigated the difference between mean 302 PIP for lead variants and fraction of lead variants that are nonsynonymous; assuming that 303 nonsynonymous variants in these loci are truly causal, this difference equals the difference 304 between the true and reported fraction of lead PIP variants that are causal. We observed 305 differences between 26-51% and 10-18% under different PIP thresholds in suspicious and non-306 suspicious loci, respectively (Fig. 4b), marking 45% and 15% for high-PIP (> 0.9) variants. 307

308 We further assessed SLALOM performance in the GWAS Catalog meta-analyses by leveraging 309 high-PIP (> 0.9) complex trait and *cis*-eQTL variants that were rigorously fine-mapped<sup>16,17</sup> in largescale biobanks (Biobank Japan [BBJ]<sup>58</sup>, FinnGen<sup>20</sup>, and UK Biobank [UKBB]<sup>19</sup>) and eQTL 310 resources (GTEx<sup>59</sup> v8 and eQTL Catalogue<sup>60</sup>). Among the 27,713 loci analyzed by SLALOM 311 312 (maximum PIP > 0.1) that contain a lead variant that was included in biobank fine-mapping, 17%313 (3,266 / 19,692) of the non-suspicious loci successfully fine-mapped one of the high-PIP GWAS variants in biobank fine-mapping, whereas 7% (589 / 8,021) of suspicious loci did, showing a 314 315 significant depletion (2.3x) of the high-PIP complex trait variants in suspicious loci (Fisher's exact 316  $P = 4.6 \times 10^{-100}$ ; Fig. 4c). Similarly, among 26,901 loci analyzed by SLALOM that contain a lead 317 variant that was included in *cis*-eQTL fine-mapping, we found a significant depletion (1.9x) of the 318 high-PIP cis-eQTL variants in suspicious loci, where 7% (1,247 / 18,976) of non-suspicious loci 319 vs. 4% (281 / 7.925) of suspicious loci successfully fine-mapped one of the high-PIP cis-eQTL variants (Fisher's exact  $P = 2.6 \times 10^{-24}$ ; Fig. 4d). We observed the same significant depletions of 320 321 the high-PIP complex trait and *cis*-eQTL variants in suspicious loci that belonged to 95% and 99% 322 CS set (Fia. 4c.d).

- 323
- 324



325 326 327 328 329 330 331 332 333 Fig. 4 | Evaluation of SLALOM performance in the GWAS Catalog summary statistics. a,c,d. Depletion of likely causal variants in predicted suspicious loci. We evaluated whether (a) nonsynonymous coding variants (pLoF and missense), (c) high-PIP (> 0.9) complex trait variants in biobank fine-mapping, and (d) high-PIP (> 0.9) cis-eQTL variants in GTEx v8 and eQTL Catalogue were lead PIP variants, in 95% CS, or in 99% CS in suspicious vs. nonsuspicious loci. Depletion was calculated by relative risk (i.e. a ratio of proportions; Methods). Error bars, invisible due to their small size, correspond to 95% confidence intervals using bootstrapping. Significance represents a Fisher's exact test *P*-value (\*, P < 0.05; \*\*, < 0.01; \*\*\*, < 0.001; \*\*\*\*, < 10<sup>-4</sup>). **b**. Plot of the estimated difference between true and reported proportion of causal variants in the loci tagging nonsynonymous variants ( $r^2 > 0.6$  with the lead variants) 334 in the GWAS Catalog under different PIP thresholds. Analogous to Fig. 3b, assuming nonsynonymous variants in these 335 loci are truly causal, the mean PIP for lead variants minus the fraction of lead variants that are nonsynonymous above 336 the threshold is equal to the difference between true and reported proportion of causal variants. 337

#### 338 Suspicious loci for fine-mapping in the GBMI summary statistics

339 Next, we applied SLALOM to meta-analysis summary statistics of 14 disease endpoints from the 340 GBMI<sup>10</sup>. These summary statistics were generated from a meta-analysis of up to 1.8 million 341 individuals in total across 18 biobanks for discovery, representing six different genetic ancestry 342 groups of approximately 33,000 African, 18,000 Admixed American, 31,000 Central and South 343 Asian, 341,000 East Asian, 1.4 million European, and 1,600 Middle Eastern individuals (Table S8). Among 489 genome-wide significant loci across the 14 traits (excluding the maior 344 345 histocompatibility complex [MHC] region, Methods), we found that 82 loci (17%) showed maximum PIP < 0.1, thus not being further considered by SLALOM. Of the remaining 407 loci 346 347 with maximum PIP > 0.1, SLALOM identified that 272 loci (67%) were suspicious loci for fine-348 mapping (Fig. 5a: Table S9). The fraction of suspicious loci and their maximum PIP varied by 349 trait, reflecting different levels of statistical power (e.g., sample sizes, heritability, and local LD 350 structure) as well as inter-cohort heterogeneity (Fig. 5b-o).

351

352 While the fraction of suspicious loci (67%) in the GBMI meta-analyses is higher than in the GWAS 353 Catalog (28%), there might be multiple reasons for this discrepancy, including association significance, sample size, ancestral diversity, and study-specific QC criteria. For example, the 354 355 GBMI summary statistics were generated from multi-ancestry, large-scale meta-analyses of 356 median sample size of 1.4 million individuals across six ancestries, while 63% of the 467 summary 357 statistics from the GWAS Catalog were only in European-ancestry studies and 83% had less than 358 0.5 million discovery samples. Nonetheless, predicted suspicious loci for fine-mapping were 359 prevalent in both the GWAS Catalog and the GBMI.









Using nonsynonymous (pLoF and missense) and high-PIP (> 0.9) complex trait and *cis*-eQTL variants, we recapitulated a significant depletion of these likely causal variants in predicted suspicious loci (2.7x, 5.2x, and 5.1x for nonsynonymous, high-PIP complex trait, and high-PIP *cis*-eQTL variants being a lead PIP variant, respectively; Fisher's exact  $P < 7.3 \times 10^{-4}$ ), confirming our observation in the GWAS Catalog analysis (**Fig. 6a–c**).

375

In 15/23 non-suspicious loci harboring a nonsynonymous variant, the nonsynonymous variant had the highest PIP. These included known missense variants such as rs116483731 (p.Arg20Gln) in *SPDL1* for idiopathic pulmonary fibrosis (IPF)<sup>61,62</sup> and rs28929474 (p.Glu366Lys) in *SERPINA1* for chronic obstructive pulmonary disease (COPD)<sup>63,64</sup>. In addition, we observed successful finemapping in 2 novel loci for asthma, i) rs41286560 (p.Pro558Thr) in *RTL1*, a missense variant known for decreasing height<sup>65,66</sup> and ii) rs34187696 (p.Gly337Val) in *ZSCAN5A*, a known missense variant for increasing monocyte count<sup>30</sup>.

383

384 To characterize fine-mapping failures in suspicious loci, we examined suspicious loci in which a 385 nonsynonymous variant did not achieve the highest PIP. For example, the FCGR2A/FCGR3A 386 (1q23.3) locus for COPD contained a genome-wide significant lead intergenic variant rs2099684 387  $(P = 1.7 \times 10^{-11})$  which is in LD  $(r^2 = 0.92)$  with a missense variant rs396991 (p.Phe176Val) of 388 FCGR3A (Fig. 6d). This locus was not previously reported for COPD, but is known for associations with autoimmune diseases (e.g., inflammatory bowel disease<sup>44</sup>, rheumatoid 389 arthritis<sup>7</sup>, and systemic lupus erythematosus<sup>67</sup>) and encodes the low-affinity human FC-gamma 390 391 receptors that bind to the Fc region of IgG and activate immune responses<sup>68</sup>. Notably, this locus 392 contains copy number variations that contribute to the disease associations in addition to singlenucleotide variants, which makes genotyping challenging<sup>68,69</sup>. Despite strong LD with the lead 393 variant, rs396991 did not achieve genome-wide significance ( $P = 9.1 \times 10^{-3}$ ), showing a significant 394 deviation from the expected association ( $P_{\text{DENTIST-S}} = 5.3 \times 10^{-41}$ ; Fig. 6e). This is primarily due to 395 396 missingness of rs396991 in 8 biobanks out of 17 ( $N_{eff}$  = 76,790 and 36,781 for rs2099684 and rs396991, respectively; Fig. 6f), which is caused by its absence from major imputation reference 397 panels (e.g., 1000GP<sup>49</sup>, HRC<sup>50</sup>, and UK10K<sup>70</sup>) despite having a high MAF in every population 398 (MAF = 0.24-0.34 in African, admixed American, East Asian, European, and South Asian 399 400 populations of anomAD<sup>57</sup>). 401

Sample size imbalance across variants was pervasive in the GBMI meta-analyses<sup>71</sup>, and was 402 403 especially enriched in predicted suspicious loci-84% of suspicious loci vs. 24% of non-404 suspicious loci showed a maximum/minimum effective sample size ratio > 2 among variants in 405 LD ( $r^2 > 0.6$ ) with lead variants (a median ratio = 4.2 and 1.2 in suspicious and non-suspicious 406 loci, respectively; Fig. S11). These observations are consistent with our simulations, 407 recapitulating that sample size imbalance results in miscalibration for meta-analysis fine-mapping. 408 Notably, we observed a similar issue in other GBMI downstream analyses (e.g., polygenic risk 409 score [PRS]<sup>71</sup> and drug discovery<sup>72</sup>), where predictive performance improved significantly after 410 filtering out variants with maximum  $N_{\rm eff}$  < 50%. Although fine-mapping methods cannot simply 411 take this approach because it inevitably reduces calibration and recall by removing true causal 412 variants, other meta-analysis downstream analyses that primarily rely on polygenic signals rather 413 than individual variants should consider this filtering as an extra QC step.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.16.22272457; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



417 418 419 420

415 416 Fig. 6 | Evaluation of SLALOM performance in the GBMI summary statistics. a-c. Similar to Fig. 4, we evaluated whether (a) nonsynonymous coding variants (pLoF and missense), (b) high-PIP (> 0.9) complex trait variants in biobank fine-mapping, and (c) high-PIP (> 0.9) cis-eQTL variants in GTEx v8 and eQTL Catalogue were lead PIP variants, in 95% CS, or in 99% CS in suspicious vs. non-suspicious loci. Depletion was calculated by relative risk (i.e. a ratio of proportions; Methods). Error bars correspond to 95% confidence intervals using bootstrapping. Significance represents a Fisher's exact test *P*-value (\*, *P* < 0.05; \*\*, < 0.01; \*\*\*, < 0.001; \*\*\*\*, < 10<sup>-4</sup>). d. Locuszoom plot of the 1q23.3 locus 421 422 for COPD. The top panel shows a Manhattan plot, where the lead variant rs2099684 (purple diamond) and a missense 423 variant rs396991 (orange diamond) are highlighted. Color represents  $r^2$  values to the lead variant. Horizontal line 424 represents a genome-wide significance threshold ( $P = 5.0 \times 10^{-8}$ ). The middle panel shows PIP from ABF fine-mapping. 425 Color represents whether variants belong to a 95% CS. The bottom panel shows  $r^2$  values with the lead variant in 426 gnomAD populations. e. A diagnosis plot showing  $r^2$  values to the lead variant vs. marginal  $\chi^2$ . Color represents  $-\log_{10}$ 427 P<sub>DENTIST-S</sub> values. Outlier variants with P<sub>DENTIST-S</sub> < 10<sup>-4</sup> are depicted in red with a diamond shape. Diagonal line 428 represents an expected marginal association. Horizontal line represents a genome-wide significance threshold. f. Z-429 scores of the lead variant (rs2099684) vs. the missense variant (rs396991) in the constituent cohorts of the meta-430 analysis. Open and closed circles represent whether both variants exist in a cohort or rs396991 is missing. Circle size 431 corresponds to an effective sample size. Color represents genetic ancestry.

# 432 Comparison of fine-mapping results between the GBMI meta-analyses and individual 433 biobanks

Motivated by successful validation of SLALOM performance, we investigated whether finemapping confidence and resolution were improved in the GBMI meta-analyses over individual biobanks. To this end, we used our fine-mapping results<sup>16,17</sup> of nine disease endpoints (asthma<sup>64</sup>, COPD<sup>64</sup>, gout, heart failure<sup>73</sup>, IPF<sup>62</sup>, primary open angle glaucoma<sup>74</sup>, thyroid cancer, stroke<sup>75</sup>, and venous thromboembolism<sup>76</sup>) in BBJ<sup>58</sup>, FinnGen<sup>20</sup>, and UKBB<sup>19</sup> Europeans that also contributed to the GBMI meta-analyses for the same traits.

440

To perform an unbiased comparison of PIP between the GBMI meta-analysis and individual 441 442 biobanks, we investigated functional enrichment of fine-mapped variants based on top PIP 443 rankings in the GBMI and individual biobanks (top 0.5%, 0.1%, and 0.05% PIP variants in the 444 GBMI vs. maximum PIP across BBJ, FinnGen, and UKBB; Methods). Previous studies have 445 shown that high-PIP (> 0.9) complex trait variants are significantly enriched for well-known 446 functional categories, such as coding (pLoF, missense, and synonymous), 5'/3' UTR, promoter, 447 and *cis*-regulatory element (CRE) regions (DNase I hypersensitive sites [DHS] and H3K27ac)<sup>16,17</sup>. 448 Using these functional categories, we found no significant enrichment of variants in the top PIP 449 rankings in the GBMI over individual biobanks (Fisher's exact P > 0.05; Fig. 7a) except for variants in the promoter region (1.8x; Fisher's exact  $P = 4.9 \times 10^{-4}$  for the top 0.1% PIP variants). We 450 451 observed similar trends regardless of whether variants were in suspicious or non-suspicious loci 452 (Fig. 7b.c). To examine patterns of increased and decreased PIP for individual variants, we also 453 calculated PIP difference between the GBMI and individual biobanks, defined as  $\Delta PIP = PIP$ 454 (GBMI) - maximum PIP across BBJ, FinnGen, and UKBB (Fig. S12,13). We investigated 455 functional enrichment based on  $\Delta PIP$  bins and observed inconsistent enrichment results using 456 different  $\Delta PIP$  thresholds (Fig. S14). Finally, to test whether fine-mapping resolution was 457 improved in the GBMI over individual biobanks, we compared the size of 95% CS after restricting 458 them to cases where a GBMI CS overlapped with an individual biobank CS from BBJ, FinnGen, or UKBB (Methods). We observed the median 95% CS size of 2 and 2 in non-suspicious loci for 459 460 the GBMI and individual biobanks, respectively, and 5 and 14 in suspicious loci, respectively (Fig. 461 **S15**). The smaller credible set size in suspicious loci in GBMI could be due to improved resolution 462 or to increased miscalibration. These results provide limited evidence of overall fine-mapping improvement in the GBMI meta-analyses over what is achievable by taking the best result from 463 464 individual biobanks.

465

466 Individual examples, however, provide insights into the types of fine-mapping differences that can 467 occur. To characterize the observed differences in fine-mapping confidence and resolution, we 468 further examined non-suspicious loci with  $\Delta PIP > 0.5$  in asthma. In some cases, the increased 469 power and/or ancestral diversity of GBMI led to improved fine-mapping: for example, an intergenic 470 variant rs1888909 (~18 kb upstream of *IL33*) showed  $\Delta PIP = 0.99$  (PIP = 1.0 and 0.008 in GBMI 471 and FinnGen, respectively; Fig. 7d), which was primarily owing to increased association significance in a meta-analysis ( $P = 3.0 \times 10^{-86}$ , 7.4 × 10<sup>-2</sup>, 3.6 × 10<sup>-16</sup>, and 1.9 × 10<sup>-53</sup> in GBMI, 472 BBJ, FinnGen, and UKBB Europeans, respectively) as well as a shorter LD length in the African 473 474 population than in the European population (LD length = 4 kb vs. 41 kb for variants with  $r^2 > 0.6$ with rs1888909 in the African and European populations, respectively;  $N_{\text{eff}} = 4,270$  for Africans in 475 476 the GBMI asthma meta-analysis; Fig. S16). This variant was also fine-mapped for eosinophil count in UKBB Europeans (PIP = 1.0;  $P = 1.3 \times 10^{-314}$ )<sup>16</sup> and was previously reported to regulate 477 IL33 gene expression in human airway epithelial cells via allele-specific transcription factor 478 479 binding of OCT-1 (POU2F1)<sup>77</sup>. Likewise, we observed a missense variant rs16903574 480 (p.Phe319Leu) in OTULINL showed  $\Delta PIP = 0.79$  (PIP = 1.0 and 0.21 in GBMI and UKBB

481 Europeans, respectively; **Fig. 7e**) owing to improved association significance ( $P = 7.7 \times 10^{-15}$  and 482  $4.7 \times 10^{-12}$  in GBMI and UKBB Europeans, respectively).

483

However, we also observed very high  $\Delta PIP$  for variants that are not likely causal. For example, 484 485 we observed that an intronic variant rs1295686 in *IL13* showed  $\Delta PIP = 0.56$  (PIP = 0.56 and 486 0.0002 in GBMI and UKBB Europeans, respectively; Fig. 7f), despite having strong LD with a 487 nearby missense variant rs20541 (p.Gln144Arg;  $r^2 = 0.96$  with rs1295686) which only showed 488  $\Delta PIP = 0.13$  (PIP = 0.13 and 0.0001 in GBMI and UKBB Europeans, respectively). The missense 489 variant rs20541 showed PIP = 0.23 and 0.15 for a related allergic disease, atopic dermatitis, in BBJ and FinnGen, respectively<sup>17</sup>, and was previously shown to induce STAT6 phosphorylation 490 and up-regulate CD23 expression in monocytes, promoting IgE synthesis<sup>78</sup>. Although the GBMI 491 492 meta-analysis contributed to prioritizing these two variants (sum of PIP = 0.69 vs. 0.0003 in GBMI 493 and UKBB Europeans, respectively), the observed  $\Delta PIP$  was higher for rs1295686 than for 494 rs20541.

495

496 While increasing sample size in meta-analysis improves association significance, we also found 497 negative  $\Delta PIP$  due to losing the ability to model multiple causal variants. A stop-gained variant 498 rs61816761 (p.Arg501Ter) in *FLG* showed  $\Delta PIP = -1.0$  (PIP = 6.4 × 10<sup>-5</sup> and 1.0 in GBMI and UKBB Europeans, respectively; Fig. 7g), which was primarily owing to a nearby lead variant 499 rs12123821 (~17 kb downstream of HRNR;  $r^2 = 0.0$  with rs61816761). This lead variant 500 501 rs12123821 showed greater significance than rs61816761 in GBMI ( $P = 9.3 \times 10^{-16}$  and  $2.0 \times 10^{-16}$ 502 <sup>11</sup> for rs12123821 and rs61816761, respectively) as well as in UKBB Europeans ( $P = 7.1 \times 10^{-26}$ and  $1.5 \times 10^{-18}$ ). While our biobank fine-mapping<sup>16,17</sup> assigned PIP = 1.0 for both variants based 503 on multiple causal variant fine-mapping (*i.e.*, FINEMAP<sup>21</sup> and SuSiE<sup>23</sup>), our ABF fine-mapping in 504 505 the GBMI meta-analysis was only able to assign PIP = 0.74 for the lead variant rs12123821 due 506 to a single causal variant assumption. This recapitulates the importance of multiple causal variant fine-mapping in complex trait fine-mapping<sup>16,17</sup>—however, we note that multiple causal variant 507 fine-mapping with an external LD reference is extremely error-prone as previously reported<sup>14–16</sup>. 508



**Fig. 7 | Fine-mapping improvement and retrogression in the GBMI meta-analyses over individual biobanks. a**– **c.** Functional enrichment of variants in each functional category based on top PIP rankings in the GBMI and individual biobanks (maximum PIP of BBJ, FinnGen, and UKBB). Shape corresponds to top PIP ranking (top 0.5%, 0.1%, and 0.05%). Enrichment was calculated by a relative risk (*i.e.* a ratio of proportions; **Methods**). Error bars correspond to 95% confidence intervals using bootstrapping. **d–g.** Locuszoom plots for the same non-suspicious locus of asthma in the GBMI meta-analysis and an individual biobank (BBJ, FinnGen, or UKBB Europeans) that showed the highest PIP in our biobank fine-mapping. Colors in the Manhattan panels represent r2 values to the lead variant. In the PIP panels, only fine-mapped variants in the 95% CS are colored, where the same colors are applied between the GBMI metaanalysis and an individual biobank based on merged CS as previously described. Horizontal line represents a genomewide significance threshold ( $P = 5.0 \times 10^{-8}$ ). **d.** rs1888909 for asthma in the GBMI and FinnGen. **e.** rs16903574 for asthma in the GBMI and UKBB Europeans. Nearby rs528167451 was also highlighted, which was in strong LD ( $r^2$  = 0.86) and in the same 95% CS in UKBB Europeans, but not in the GBMI ( $r^2 = 0.67$ ). **f.** rs1295686 for asthma in the

522 GBMI and UKBB Europeans. A nearby missense, rs20541, showed lower PIP than rs1295686 despite having strong 523 LD ( $r^2 = 0.96$ ). **g**. rs12123821 for asthma in the GBMI and UKBB Europeans. Nearby stop-gained rs61816761 was 524 independent of rs12123821 ( $r^2 = 0.0$ ) and not fine-mapped in the GBMI due to a single causal variant assumption in 525 the ABF fine-mapping.

526

#### 527 Discussion

528 In this study, we first demonstrated in simulations that meta-analysis fine-mapping is substantially 529 miscalibrated when constituent cohorts are heterogeneous in phenotyping, genotyping, and 530 imputation. To mitigate this issue, we developed SLALOM, a summary statistics-based QC 531 method for identifying suspicious loci in meta-analysis fine-mapping. Applying SLALOM to 14 disease endpoints from the GBMI meta-analyses<sup>10</sup> as well as 467 summary statistics from the 532 GWAS Catalog<sup>48</sup>, we observed widespread suspicious loci in meta-analysis summary statistics, 533 534 suggesting that meta-analysis fine-mapping is often miscalibrated in real data too. Indeed, we 535 demonstrated that the predicted suspicious loci were significantly depleted for having likely causal 536 variants as a lead PIP variant, such as nonsynonymous variants, high-PIP (> 0.9) GWAS and ciseQTL fine-mapped variants from our previous fine-mapping studies<sup>16,17</sup>. Our method provides 537 538 better calibration in non-suspicious loci for meta-analysis fine-mapping, generating a more reliable 539 set of variants for further functional characterization.

540

541 We have found limited evidence of improved fine-mapping in the GBMI meta-analyses over 542 individual biobanks. A few empirical examples in this study as well as other previous studies7,9,26,27,30 suggested that multi-ancestry, large-scale meta-analysis could have potential to 543 544 improve fine-mapping confidence and resolution owing to increased statistical power in 545 associations and differential LD pattern across ancestries. However, we have highlighted that the 546 observed improvement in PIP could be due to sample size imbalance in a locus, miscalibration, 547 and technical confoundings too, which further emphasizes the importance of careful investigation 548 of fine-mapped variants identified through meta-analysis fine-mapping. Given practical challenges 549 in data harmonization across different cohorts, a large-scale biobank with multiple ancestries 550 (e.g., UK Biobank<sup>19</sup> and All of Us<sup>79</sup>) would likely benefit the most from meta-analysis fine-mapping 551 across ancestries.

552

553 As high-confidence fine-mapping results in large-scale biobanks and molecular QTLs continue to become available<sup>16,17,60</sup>, we propose alternative approaches for prioritizing candidate causal 554 555 variants in a meta-analysis. First, these high-confidence fine-mapped variants have been a valuable resource to conduct a "PheWAS"<sup>16</sup> to match with associated variants in a meta-analysis, 556 557 which provides a narrower list of candidate variants assuming they would equally be functional and causal in related complex traits or tissues/cell-types. Second, a traditional approach based 558 on tagging variants (e.g.,  $r^2 > 0.6$  with lead variants, or PICS<sup>80</sup> fine-mapping approach that only 559 relies on a lead variant and LD) can be still highly effective, especially for known functional 560 variants such as nonsynonymous coding variants. As we highlighted in this and previous<sup>39</sup> 561 562 studies, potentially causal variants in strong LD with lead variants might not achieve genome-563 wide significance because of missingness and heterogeneity. 564

565 While using an external LD reference for fine-mapping has been shown to be extremely error-566 prone<sup>14–16</sup>, we find here that it can be useful for flagging suspicious loci, even when it does not 567 perfectly represent the in-sample LD structure of the meta-analyzed individuals. However, our 568 use of external LD reference comes with several limitations. For example, due to the finite sample 569 size of external LD reference, rare or low-frequency variants have larger uncertainties around  $r^2$ 570 than common variants. Moreover, our  $r^2$  values in a multi-ancestry meta-analysis are currently

approximated based on a sample-size-weighted average of  $r^2$  across ancestries as previously 571 suggested<sup>81</sup>, but this can be different from actual  $r^2$ . These uncertainties around  $r^2$  affect SLALOM 572 573 prediction performance and should be modeled appropriately for further method development. On 574 the other hand, we find it challenging to use a LD reference when true causal variants are located 575 within a complex region (e.g., major histocompatibility complex [MHC]), or are entirely missing 576 from standard LD or imputation reference panels, especially for structural variants. These 577 limitations are not specific to meta-analysis fine-mapping, and separate fine-mapping methods based on bespoke imputation references have been developed (e.g., HLA<sup>82</sup>, KIR<sup>83</sup>, and variable 578 numbers of tandem repeats [VNTR]<sup>84</sup>). 579

580

581 In addition, there are several methodological limitations of SLALOM. First, our simulations only 582 include one causal variant per locus. Although additional independent causal variants would not 583 affect SLALOM precision (but decrease recall), multiple correlated causal variants in a locus 584 would violate SLALOM assumptions and could lead to some DENTIST-S outliers that are not due 585 to heterogeneity or missingness but rather simply a product of tagging multiple causal variants in 586 LD. In fact, our previous studies have illustrated infrequent but non-zero presence of such correlated causal variants in complex traits<sup>16,17</sup>. Second, SLALOM prediction is not perfect. 587 588 Although fine-mapping calibration is certainly better in non-suspicious vs. suspicious loci, 589 SLALOM has low precision, and we still observe some miscalibration in non-suspicious loci. 590 Optimal thresholds for SLALOM prediction might be different for other datasets. Third, SLALOM 591 does not model effect size heterogeneity. Although SLALOM is able to detect suspicious loci due 592 to effect size heterogeneity as the method is agnostic to the source of heterogeneity, methods which model effect size heterogeneity, such as MR-MEGA<sup>85</sup>, could improve SLALOM 593 performance. Finally, SLALOM is a per-locus QC method and does not calibrate per-variant PIPs. 594 595 Further methodological development that properly models heterogeneity, missingness, sample 596 size imbalance, multiple causal variants, and LD uncertainty across multiple cohorts and 597 ancestries is needed to refine per-variant calibration and recall in meta-analysis fine-mapping.

598

599 We have found evidence in our simulations and real data of severe miscalibration of fine-mapping 600 results from GWAS meta-analysis; for example, we estimate that the difference between true and 601 reported proportion of causal variants is 20% and 45% for high-PIP (> 0.9) variants in suspicious 602 loci from the simulations and the GWAS Catalog, respectively. Our SLALOM method helps to 603 exclude spurious results from meta-analysis fine-mapping; however, even fine-mapping results in 604 SLALOM-predicted "non-suspicious" loci remain somewhat miscalibrated, showing estimated 605 differences between true and reported proportion of causal variants of 4% and 15% for high-PIP 606 variants in the simulations and the GWAS Catalog, respectively. We thus urge extreme caution 607 when interpreting PIPs computed from meta-analyses until improved methods are available. We 608 recommend that researchers looking to identify likely causal variants employ complete 609 synchronization of study design, case/control ascertainment, genomic profiling, and analytical 610 pipeline, or rely more heavily on functional annotations, biobank fine-mapping, or molecular QTLs. 611

### 612 Acknowledgements

We acknowledge all the participants and researchers of the 23 biobanks that have contributed to the GBMI. Biobank-specific acknowledgements are included in the **Supplementary Note**. We thank H. Huang, A.R. Martin, B.M. Neale, Y. Okada, K. Tsuo, J.C. Ulirsch, Y. Wang, and all the members of Finucane and Daly labs for their helpful feedback. M.K. was supported by a Nakajima Foundation Fellowship and the Masason Foundation. H.K.F. was funded by NIH grant DP5

618 OD024582.

#### 619 Author contributions

620 M.K., M.J.D, and H.K.F. designed the study. M.K., R.E. and W.Z. performed analyses. H.K.F 621 supervised this work. H.K.F. and M.K. obtained funding. M.K., R.E., M.J.D., and H.K.F. wrote the 622 manuscript with input from all authors.

#### 623 Competing interests

624 M.J.D. is a founder of Maze Therapeutics. All other authors declare no competing interests.

#### 625 STAR Methods

#### 626 **Resource availability**

#### 627 Lead contact

Further information and requests for resources and data should be directed to and will be fulfilled by the lead contact, Masahiro Kanai (mkanai@broadinstitute.org).

#### 630 Materials availability

631 This study did not generate new unique reagents.

#### 632 Data and code availability

The GBMI summary statistics for the 14 endpoints are publicly available and are browserble at the GBMI PheWeb website (<u>http://results.globalbiobankmeta.org/</u>). Example outputs from the meta-analysis fine-mapping simulation pipeline have been deposited at Harvard Dataverse. All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOIs and links are listed in the key resources table. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

## 639 Method details

#### 640 Meta-analysis fine-mapping simulation

To benchmark fine-mapping performance in meta-analysis, we simulated a large-scale, realistic

- 642 GWAS meta-analysis and performed fine-mapping under different scenarios. An overview of our
- simulation pipeline is summarized in **Fig. S2**.

#### 644 *Simulated true genotype*

Using HAPGEN2<sup>87</sup> with the 1000 Genomes Project Phase 3 reference<sup>49</sup>, we simulated "true" 645 genotypes of chromosome 3 for multiple independent cohorts from African. East Asian, and 646 647 European ancestries. For each independent cohort from a given ancestry, we simulated 10,000 648 individuals each using the default parameters, with an ancestry-specific effective population size 649 set to 17,469, 14,269, and 11,418 for Africans, East Asians, and Europeans, respectively, as recommended<sup>87</sup>. To mimic sample size imbalance of different ancestries in the current meta-650 651 analyses, we simulated 10 independent European cohorts, 1 African cohort, and 1 East Asian 652 cohort.

653

To restrict our analysis to unrelated samples, we computed sample relatedness based on KING kinship coefficients<sup>88</sup> using PLINK 2.0 (ref. <sup>89</sup>) and removed monozygotic twins, duplicated individuals, or first-degree relatives with the coefficient threshold of 0.177. The detailed sample sizes of unrelated individuals for each cohort is summarized in **Table S1**.

#### 658 Genotyping and imputation

659 To simulate realistic genotyping and imputation procedures, we first virtually genotyped each 660 cohort by restricting variants to those that are available on different genotyping arrays. We 661 selected three major genotyping arrays from Illumina, Inc. (Omni2.5, Multi-Ethnic Global Array 662 [MEGA], and Global Screening Array [GSA]) that have different densities of genotyping probes 663 (**Table S2**). For each cohort, we created three virtually genotyped datasets by retaining variants 664 that are genotyped on each array. For the sake of simplicity, we assumed no genotyping errors 665 occurred between true genotypes and virtually genotyped data-however, in practice, genotyping 666 error is one of the major sources of unexpected confounding (e.g., see recent discussions here<sup>90,91</sup>) and should be treated carefully. 667

668

669 For each pair of cohort and genotyping array, we then imputed missing variants using different 670 imputation reference panels. We Michigan Imputation Server used the (https://imputationserver.sph.umich.edu/)92 671 and the TOPMed Imputation Server (https://imputation.biodatacatalyst.nhlbi.nih.gov/)<sup>51</sup> with the default parameters, using three 672 publicly available reference panels: the 1000 Genomes Project Phase 3 (version 5: n = 2.504: 673 1000GP3)<sup>49</sup>, the Haplotype Reference Consortium (version r1.1; n = 32,470; HRC)<sup>50</sup>, and the 674 TOPMed (version R2; n = 97,256)<sup>51</sup>. Briefly, for each input, the imputation server created chunks 675 of 20 Mb, applied the standard QC, pre-phased each chunk with Eagle2 (ref. 93), and imputed 676 677 non-genotyped variants using а specified reference panel with Minimac4 678 (https://genome.sph.umich.edu/wiki/Minimac4). The detailed documentation of the imputation 679 pipeline is available on the Michigan and TOPMed websites and has been described elsewhere<sup>92</sup>. 680

681 We applied post-imputation QC by only keeping variants with MAF > 0.001 and imputation Rsq > 682 0.6. Because the TOPMed panel is based on GRCh38 while the 1000GP3 and the HRC panels 683 are on GRCh37, we lifted over TOPMed variants from GRCh38 to GRCh37 to meta-analyze with 684 other cohorts. We excluded any variants which were lifted over to different chromosomes or for 685 which the conversion failed. The number of virtually genotyped and imputed variants for each 686 combination of cohort, genotyping array, and imputation panel is summarized in **Table S3**.

#### 687 True phenotype

688 We simulated 300 true phenotypes that resemble observed complex trait genetic architecture and 689 phenotypic heterogeneity across cohorts. Based on previous literature, we set parameters as 690 follows: 1) 50% of 1 Mb loci contain a true causal variant<sup>94</sup>; 2) probability of being causal is

691 proportional to functional enrichments of variant consequences (pLoF, missense, synonymous, 692 5'/3' UTR, promoter, cis-regulatory region, and non-genic) for fine-mapped variants as estimated 693 in a previous complex trait fine-mapping study<sup>17</sup>; 3) per-allele causal effect sizes have a variance 694 proportional to  $[2p(1-p)]^{\alpha}$  where p represents a maximum MAF across the three ancestries (AFR, EAS, and EUR) and  $\alpha$  is set to be -0.38 (ref. <sup>52</sup>); and 4) total SNP-heritability  $h_g^2$  for chromosome 3 equals 0.03 (ref. <sup>53</sup>). For the sake of simplicity, we randomly draw a single true 695 696 causal variant per locus because ABF assumes a single causal variant<sup>31,32</sup>. We draw true causal 697 698 variants from 1,150,893 non-ambiguous single-nucleotide variants in 1000GP3 that showed MAF > 0.01 in at least one of the three ancestries (AFR, EAS, or EUR) and were not located within 699 conversion-unstable positions (CUP)<sup>54</sup> between the human genome builds GRCh37 and 700 GRCh38. To mimic phenotypic heterogeneity across cohorts in real-world meta-analysis (due to 701 702 e.g., different ascertainment, measurement error, or true effect size heterogeneity), we introduced 703 cross-cohort genetic correlation of true effect sizes  $r_g$  which is set to be one of 1, 0.9, or 0.5. For a true causal variant j, true causal effect sizes  $\beta_i$  across cohorts were randomly drawn from  $\beta_i \sim$ 704  $MVN(0,\Sigma)$  where diagonal elements of  $\Sigma$  were set to be  $\sigma_g^2 \cdot [2p(1-p)]^{\alpha}$  and off-diagonal elements of  $\Sigma$  were set to be  $r_g \cdot \sigma_g^2 \cdot [2p(1-p)]^{\alpha}$ .  $\sigma_g^2$  was determined by  $\sigma_g^2 = h_g^2/2$ 705 706 707  $\sum_{i} [2p(1-p)]^{1+\alpha}$ . For each cohort, true phenotype y was computed via  $y = X\beta + \varepsilon$  where X is the above true genotype matrix from HAPGEN2 and  $\varepsilon_i \sim N(0, 1 - \sigma_q^2)$  i.i.d. We simulated 100 708 true phenotypes for each of  $r_q$  = 1, 0.9, and 0.5, respectively. 709

#### 710 GWAS

For each combination of phenotype, cohort, genotyping chip, and imputation panel, we conducted GWAS via a standard linear regression as implemented in PLINK 2.0 using imputed dosages. For covariates, we included top 10 principal components that were calculated based on true genotypes after restricting to unrelated samples. We only used LD-pruned variants with MAF > 0.01 for PCA.

#### 716 Meta-analysis

717 To simulate meta-analyses that resemble real-world settings, we generated multiple 718 configurations of the above GWAS results to meta-analyze across 10 independent cohorts. 719 Briefly, we chose configurations based on the following settings: 1) 10 EUR cohorts are genotyped 720 and imputed using the same genotyping array (one of GSA, MEGA, or Omni2.5) and the same 721 imputation panel (one of 1000GP3, HRC, TOPMed, or TOPMed-liftover); 2) 10 cohorts consisting 722 of multiple ancestries (9 EUR + 1 AFR/EAS cohorts or 8 EUR + 1 AFR + 1 EAS cohorts), with all 723 cohorts genotyped and imputed using the same array (Omni2.5) and the same panel (1000GP3); 724 3) 10 EUR or multi-ancestry cohorts are genotyped using the same array (Omni2.5) but imputed 725 using different panels across cohorts; 4) 10 EUR or multi-ancestry cohorts are imputed using the 726 same panel (1000GP3) but genotyped using different arrays across cohorts; 5) 10 EUR or multi-727 ancestry cohorts are genotyped and imputed using different arrays and panels across cohorts. 728 For settings 3–5, we randomly draw a combination of a genotyping array and an imputation panel 729 for each cohort five times each for 10 EUR and multi-ancestry cohorts. In total, we generated 45 730 configurations as summarized in Table S4.

731

For each configuration, we conducted a fixed-effect meta-analysis based on inverse-variance weighted betas and standard errors using a modified version of PLINK 1.9 (https://github.com/mkanai/plink-ng/tree/add\_se\_meta).

#### 735 Fine-mapping

736 For each meta-analysis, we defined fine-mapping regions based on a 1 Mb window around each

- genome-wide significant lead variant and applied ABF<sup>31,32</sup> using prior effect size variance of  $\sigma_0^2 = 0.04$ . We set a prior variance of effect size to be 0.04 which was taken from Wakefield et al.<sup>31</sup> and 737
- 738
- is commonly used in meta-analysis fine-mapping studies<sup>2,7</sup>. We computed posterior inclusion 739
- 740 probability (PIP) and 95% credible set (CS) for each locus and evaluated whether true causal
- 741 variants were correctly fine-mapped.

#### 742 The SLALOM method

SLALOM takes GWAS summary statistics and external LD reference as input and predicts 743 whether a locus is suspicious for fine-mapping. SLALOM consists of the following three steps: 744

#### 745 Locus definition

746 Consistent with common fine-mapping region definition, we defined loci based on a 1 Mb window

- 747 around each genome-wide significant lead variant and merged them if they overlapped. We
- 748 excluded the major histocompatibility complex (MHC) region (chr 6: 25-36 Mb) from analysis due
- 749 to extensive LD structure in the region.

#### 750 **DENTIST-S** outlier detection

751 For each variant in a locus, we computed DENTIST-S statistics using equation (1) based on the assumption of a single causal variant. DENTIST-S P-values (PDENTIST-S) were computed using the 752  $\chi^2$  distribution with 1 degree of freedom. We applied ABF<sup>31,32</sup> using prior effect size variance of 753  $\sigma_0^2 = 0.04$  and used the lead PIP variant (the variant with the highest PIP) as an approximation of 754 the causal variant in the locus. To retrieve correlation r among the variants, we used publicly 755 available LD matrices from gnomAD<sup>57</sup> v2 as external LD reference for African, Admixed American, 756 757 East Asian, Finnish, and non-Finnish European populations. When multiple populations exist, we computed a sample-size-weighted average of  $r^2$  using per-variant sample sizes for each 758 population as previously suggested<sup>81</sup>. We excluded variants without  $r^2$  available in gnomAD from 759 760 the analysis. Since gnomAD v2 LD matrices are based on the human genome assembly GRCh37, 761 variants were lifted over to GRCh38 if the input summary statistics were based on GRCh38. 762

763 We determined DENTIST-S outlier variants using two thresholds: 1)  $r^2 > \rho$  to the lead and 2)  $P_{\text{DENTIST-S}} < \tau$ . The thresholds  $\rho$  and  $\tau$  were set to  $\rho = 0.6$  and  $\tau = 1.0 \times 10^{-4}$  based on the training 764 765 in simulations as described below.

#### 766 Suspicious loci prediction

767 We predicted whether a locus is suspicious or non-suspicious for fine-mapping based on the 768 number of DENTIST-S outlier variants in the locus >  $\kappa$ . To determine the best-performing 769 thresholds ( $\rho$ ,  $\tau$ , and  $\kappa$ ), we used loci with maximum PIP > 0.9 in the simulations for training. 770 Positive conditions were defined as whether a true causal variant in a locus is 1) a lead PIP 771 variant, 2) in 95% CS, and 3) in 99% CS. We computed AUROC across different thresholds ( $\rho =$ 772 0, 0.1, 0.2, ..., 0.9;  $-\log_{10} \tau = 0, 0.5, 1, ..., 10$ ; and  $\kappa = 0, 1, 2, ...$ ) and chose  $\rho = 0.6, \tau = 1.0 \times 10^{-1}$ 773 <sup>4</sup>, and  $\kappa = 0$  that showed the highest AUROC for all the aforementioned positive conditions. Using 774 all the loci in the simulations, we then evaluated fine-mapping miscalibration (defined as mean 775 PIP – fraction of true causal variants) at different PIP thresholds in suspicious and non-suspicious 776 loci and decided to only apply SLALOM to loci with maximum PIP > 0.1 owing to relatively lower 777 miscalibration and specificity of SLALOM at lower PIP thresholds.

### 778 **GWAS Catalog analysis**

We retrieved full GWAS summary statistics publicly available on the GWAS Catalog<sup>48</sup>. Out of 779 780 33,052 studies from 5,553 publications registered at the GWAS Catalog (as of January 12, 2022), 781 we selected 467 studies from 96 publications that have 1) full harmonized summary statistics 782 preprocessed by the GWAS Catalog with non-missing variant ID, marginal beta, and standard 783 error columns, 2) a discovery sample size of more than 10,000 individuals, 3) African (including 784 African American, Afro-Caribbean, and Sub-Saharan African), admixed American (Hispanic and 785 Latin American), East Asian, or European samples based on their broad ancestral category metadata, 4) at least one genome-wide significant association ( $P < 5.0 \times 10^{-8}$ ), and 5) our manual 786 787 annotation as a meta-analysis rather than a single-cohort study (Table S6). We applied SLALOM 788 to the 467 summary statistics and identified 35.864 genome-wide significant loci (based on 1 Mb 789 window around lead variants), of which 28.925 loci with maximum PIP > 0.1 were further classified 790 into suspicious and non-suspicious loci. Since per-variant sample sizes were not available, we used overall sample sizes of each ancestry (African, Admixed American, East Asian, and 791 792 European) to calculate the weighted-average of  $r^2$ . All the variants were harmonized into the 793 human genome assembly GRCh38 by the GWAS Catalog.

## 794 **GBMI analysis**

We used meta-analysis summary statistics of 14 disease endpoints from the GBMI (**Table S8**). These meta-analyses were conducted using up to 1.8 million individuals across 18 biobanks for discovery, representing six different genetic ancestry groups (approximately 33,000 African, 18,000 Admixed American, 31,000 Central and South Asian, 341,000 East Asian, 1.4 million European, and 1,600 Middle Eastern individuals). Detailed procedures of the GBMI metaanalyses were described in the GBMI flagship publication<sup>10</sup>.

801 802 Across the 14 summary statistics, we used 489 out of 500 genome-wide significant loci (P < 5.0 $\times$  10<sup>-8</sup>; 1 Mb window around each lead variant, as defined in the GBMI flagship publication<sup>10</sup>), 803 excluding 11 loci that overlap with the MHC region. We applied SLALOM to 422 loci with maximum 804 805 PIP > 0.1 based on the ABF fine-mapping and predicted whether they were suspicious or non-806 suspicious for fine-mapping. We used per-variant sample sizes of each ancestry (African, 807 Admixed American, East Asian, Finnish, and non-Finnish European) to calculate the weighted-808 average of  $r^2$ . Since gnomAD LD matrices were not available for Central and South Asian and 809 Middle Eastern, we did not use their sample sizes for the calculation. All the variants were 810 processed on the human genome assembly GRCh38.

#### 811 Fine-mapping results of complex traits and *cis*-eQTL

812 We retrieved our previous fine-mapping results for 1) complex traits in large-scale biobanks 813 (BBJ<sup>58</sup>, FinnGen<sup>20</sup>, and UKBB<sup>19</sup> Europeans)<sup>16,17</sup> and 2) *cis*-eQTLs in GTEx<sup>59</sup> v8 and eQTL 814 Catalogue<sup>60</sup>. Briefly, we conducted multiple-causal-variant fine-mapping (FINEMAP<sup>21,22</sup> and 815 SuSiE<sup>23</sup>) of complex trait GWAS (# unique traits = 148) and *cis*-eQTL gene expression (# unique 816 tissues/cell-types = 69) using summary statistics and in-sample LD. Detailed fine-mapping 817 methods are described elsewhere<sup>16,17</sup>.

818

819 In this study, we collected 1) high-PIP GWAS variants that achieved PIP > 0.9 for any traits in any 820 biobank and 2) high-PIP *cis*-eQTL variants that acheived PIP > 0.9 for any gene expression in

any tissues/cell-types. All the variants were originally processed on the human genome assembly
 GRCh37 and lifted over to the GRCh38 for comparison.

## 823 Additional fine-mapping results

824 To compare with the GBMI meta-analyses, we additionally conducted multi-causal-variant finemapping of four additional endpoints (gout, heart failure, thyroid cancer, and venous 825 826 thromboembolism) that were not fine-mapped in our previous study<sup>16,17</sup>. We used exactly the same fine-mapping pipeline (FINEMAP<sup>21,22</sup> and SuSiE<sup>23</sup>) as described previously<sup>16,17</sup>. For UKBB 827 Europeans, to use the exact same samples that contributed to the GBMI, we used individuals of 828 829 European 420,531) as defined in the Pan-UKBB ancestry (n = project 830 (https://pan.ukbb.broadinstitute.org), instead of those of "white British ancestry" (n = 361.194) 831 used in our previous study<sup>16,17</sup>.

## 832 Enrichment analysis of likely causal variants

To validate SLALOM performance, we asked whether suspicious and non-suspicious loci were enriched for having likely causal variants as a lead PIP variant, and for containing them in the 95% and 99% CS. We defined likely causal variants using 1) nonsynonymous coding variants, *i.e.*, pLoF and missense variants annotated<sup>95</sup> by the Ensembl Variant Effect Predictor (VEP) v101 (using GRCh38 and GENCODE v35), 2) the high-PIP (> 0.9) complex trait fine-mapped variants, and 3) the high-PIP (> 0.9) *cis*-eQTL fine-mapped variants from our previous studies as described above.

840

We estimated enrichment for suspicious and non-suspicious loci as a relative risk (*i.e.*, a ratio of proportion of variants) between being in suspicious/non-suspicious loci and having the annotated likely causal variants as a lead PIP variant (or containing them in the 95% or 99% CS). That is, a relative risk = (proportion of non-suspicious loci having the annotated variants as a lead PIP variant) / (proportion of suspicious loci having the annotated variants as a lead PIP computed 95% confidence intervals using bootstrapping.

#### 847 Comparison of fine-mapping results between the GBMI and individual biobanks

848 To directly compare with fine-mapping results from the GBMI meta-analyses, we used our finemapping results of nine disease endpoints (asthma<sup>64</sup>, COPD<sup>64</sup>, gout, heart failure<sup>73</sup>, IPF<sup>62</sup>, primary open angle glaucoma<sup>74</sup>, thyroid cancer, stroke<sup>75</sup>, and venous thromboembolism<sup>76</sup>) in BBJ<sup>58</sup>, 849 850 851 FinnGen<sup>20</sup>, and UKBB<sup>19</sup> Europeans that were also part of the GBMI meta-analyses for the same traits. For comparison, we computed the maximum PIP for each variant and the minimum size of 852 853 95% CS across BBJ, FinnGen, and UKBB. We restricted the 95% CS in biobanks to those that 854 contain the lead variants from the GBMI. We defined the PIP difference between the GBMI and 855 individual biobanks as  $\Delta PIP = PIP (GBMI)$  – the maximum PIP across the biobanks. 856

We conducted functional enrichment analysis to compare between the GBMI meta-analysis and 857 858 individual biobanks because unbiased comparison of PIP requires conditioning on likely causal 859 variants independent of the fine-mapping results, and functional annotations have been shown to 860 be enriched for causal variants. Using functional categories (coding [pLoF, missense, and synonymous], 5'/3' UTR, promoter, and CRE) from our previous study<sup>16,17</sup>, we estimated 861 862 functional enrichments of variants in each functional category based on 1) top PIP rankings and 863 2)  $\Delta PIP$  bins. Since fine-mapping PIP in the GBMI meta-analysis can be miscalibrated, we 864 performed a comparison based on top PIP rankings to assess whether the ordering given by 865 GBMI PIPs is more informative than the ordering given by the biobanks. For the top PIP rankings, 866 we took the top 0.5%, 0.1%, and 0.05% variants based on the PIP rankings in the GBMI and individual biobanks. We computed enrichment as a relative risk = (proportion of top X% PIP 867 868 variants in the GBMI that are in the annotation) / (proportion of top X% PIP variants in the 869 individual biobanks that are in the annotation). For  $\Delta$ PIP bins, we defined three bins using different

870 thresholds ( $\theta$  = 0.01, 0.05, and 0.1): 1) decreased PIP bin,  $\Delta$ PIP <  $-\theta$ , 2) null bin,  $-\theta \le \Delta$ PIP  $\le \theta$ ,

and 3) increased PIP bin,  $\theta < \Delta$ PIP. We computed enrichment as a relative risk = (proportion of

variants in the decreased/increased PIP bin that are in the annotation) / (proportion of variants in

- the null PIP bin). We combined coding, UTR, and promoter categories for this analysis due to the limited number of variants for each bin
- 874 limited number of variants for each bin.

## 875 **References**

- Evangelou, E. & Ioannidis, J. P. a. Meta-analysis methods for genome-wide association studies and beyond. *Nat. Rev. Genet.* 14, 379–389 (2013).
- 878
   2. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using highdensity imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505–1513 (2018).
- Spracklen, C. N. *et al.* Identification of type 2 diabetes loci in 433,540 East Asian
  individuals. *Nature* 582, 240–245 (2020).
- 882 4. Ripke, S. *et al.* Biological insights from 108 schizophrenia-associated genetic loci. *Nature*883 511, 421–427 (2014).
- The Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke, S.,
  Walters, J. T. R. & O'Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. *bioRxiv* (2020) doi:10.1101/2020.09.12.20192922.
- 887 6. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery.
   888 *Nature* 506, 376–381 (2014).
- Ishigaki, K. *et al.* Trans-ancestry genome-wide association study identifies novel genetic
   mechanisms in rheumatoid arthritis. *bioRxiv* (2021) doi:10.1101/2021.12.01.21267132.
- 891 8. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity
  biology. *Nature* **518**, 197–206 (2015).
- 893 9. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of
  894 lipids. *Nature* 600, 675–679 (2021).
- 895 10. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: powering genetic discovery across
   896 human diseases. *bioRxiv* (2021) doi:10.1101/2021.11.19.21266436.
- 897 11. Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation.
  898 *Am. J. Hum. Genet.* **101**, 5–22 (2017).
- Shendure, J., Findlay, G. M. & Snyder, M. W. Genomic Medicine-Progress, Pitfalls, and
   Promise. *Cell* **177**, 45–57 (2019).
- Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate
   causal variants by statistical fine-mapping. *Nat. Rev. Genet.* **19**, 491–504 (2018).
- 903 14. Ulirsch, J. C. *et al.* Interrogation of human hematopoiesis at single-cell and single-variant
   904 resolution. *Nat. Genet.* **51**, 683–693 (2019).
- 15. Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of complex trait heritability. *Nat. Genet.* **52**, 1355–1363 (2020).
- 907 16. Ulirsch, J. C. & Kanai, M. An annotated atlas of causal variants underlying complex traits
   908 and gene expression. *Under review*.
- 17. Kanai, M. *et al.* Insights from complex trait fine-mapping across diverse populations.
   medRxiv (2021) doi:10.1101/2021.09.03.21262975.
- 911 18. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *J. Epidemiol.* 27, S2–S8 (2017).
- 913 19. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
  914 *Nature* 562, 203–209 (2018).
- 20. Kurki, M. I. *et al.* FinnGen: Unique genetic insights from combining isolated population and
  national health register data. *bioRxiv* (2022) doi:10.1101/2022.03.03.22271360.
- 917 21. Benner, C. et al. FINEMAP: Efficient variable selection using summary data from genome-

- 918 wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- Benner, C., Havulinna, A. S., Salomaa, V., Ripatti, S. & Pirinen, M. Refining fine-mapping:
  effect sizes and regional heritability. *bioRxiv* 318618 (2018) doi:10.1101/318618.
- 921 23. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
  922 selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B*923 *Stat. Methodol.* 82, 1273–1300 (2020).
- 924 24. Onengut-Gumuscu, S. *et al.* Fine mapping of type 1 diabetes susceptibility loci and
  925 evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat. Genet.*926 47, 381–386 (2015).
- 25. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and metaanalysis in >1.2 million individuals highlight new therapeutic directions. *Nat. Neurosci.* 24, 954–963 (2021).
- 930 26. Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci
  931 with consistent effect across ancestries. *Nat. Commun.* 12, 1258 (2021).
- 932 27. Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.* 53, 840–860 (2021).
- 28. Zhou, W. *et al.* GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. *Nat. Commun.* **11**, 1–13 (2020).
- 936
  937
  29. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
  937 identifies new risk loci for Alzheimer's disease. *Nat. Genet.* 53, 1276–1282 (2021).
- 30. Chen, M.-H. *et al.* Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667
  Individuals from 5 Global Populations. *Cell* 182, 1198–1213.e14 (2020).
- 940 31. Wakefield, J. A Bayesian measure of the probability of false discovery in genetic
  941 epidemiology studies. *Am. J. Hum. Genet.* 81, 208–227 (2007).
- 32. Wakefield, J. Bayes factors for genome-wide association studies: comparison with Pvalues. *Genet. Epidemiol.* 33, 79–86 (2009).
- 33. Hormozdiari, F., Kostem, E., Kang, E. Y., Pasaniuc, B. & Eskin, E. Identifying Causal
  Variants at Loci with Multiple Signals of Association. *Genetics* **198**, 497–508 (2014).
- 34. Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical fine mapping studies. *PLoS Genet.* **10**, e1004722 (2014).
- 35. Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic FineMapping Studies. *Am. J. Hum. Genet.* 97, 260–271 (2015).
- 36. Li, D., Zhao, H. & Gelernter, J. Strong protective effect of the aldehyde dehydrogenase
  gene (ALDH2) 504lys (\*2) allele against alcoholism and alcohol-induced medical diseases
  in Asians. *Hum. Genet.* 131, 725–737 (2012).
- 37. Brown, B. C., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C. J.,
  Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from Summary
  Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
- 38. Shi, H. *et al.* Population-specific causal disease effect sizes in functionally important
   regions impacted by selection. *bioRxiv* 803452 (2020) doi:10.1101/803452.
- 39. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19.
   Nature 600, 472–477 (2021).
- 960 40. Dendrou, C. A. *et al.* Resolving *TYK2* locus genotype-to-phenotype differences in autoimmunity. *Sci. Transl. Med.* **8**, 363ra149 (2016).
- 962 41. Couturier, N. *et al.* Tyrosine kinase 2 variant influences T lymphocyte polarization and
   963 multiple sclerosis susceptibility. *Brain* 134, 693–703 (2011).
- 42. Li, Z. *et al.* Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. *J. Immunol.* **190**, 2335–2344 (2013).
- 43. Lam, M. *et al.* RICOPILI: Rapid Imputation for COnsortias PIpeLIne. *Bioinformatics* 36, 930–933 (2020).
- 968 44. Huang, H. et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution.

- 969 *Nature* **547**, 173–178 (2017).
- 970 45. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association metaanalyses. *Nat. Protoc.* 9, 1192–1212 (2014).
- 46. Chen, W. *et al.* Improved analyses of GWAS summary statistics by reducing data
  heterogeneity and errors. *Nat. Commun.* **12**, 7117 (2021).
- Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
  identifies additional variants influencing complex traits. *Nat. Genet.* 44, 369–75, S1–3
  (2012).
- 977 48. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
  978 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 47, D1005–
  979 D1012 (2019).
- 49. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
   Nature 526, 68–74 (2015).
- 982 50. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.* 983 *Genet.* 48, 1279–1283 (2016).
- 51. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
   *Nature* 590, 290–299 (2021).
- 52. Schoech, A. P. *et al.* Quantification of frequency-dependent genetic architectures in 25 UK
  Biobank traits reveals action of negative selection. *Nat. Commun.* **10**, 790 (2019).
- 53. Yang, J. *et al.* Genome partitioning of genetic variation for complex traits using common
  SNPs. *Nat. Genet.* 43, 519–525 (2011).
- 990 54. Ormond, C., Ryan, N. M., Corvin, A. & Heron, E. A. Converting single nucleotide variants
  991 between genome builds: from cautionary tale to solution. *Brief. Bioinform.* 22, (2021).
- 55. Asimit, J. L., Hatzikotoulas, K., McCarthy, M., Morris, A. P. & Zeggini, E. Trans-ethnic study design approaches for fine-mapping. *Eur. J. Hum. Genet.* 24, 1330–1336 (2016).
- Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat. Rev. Genet.* 11, 499–511 (2010).
- 57. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
  141,456 humans. *Nature* 581, 434–443 (2020).
- 58. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human
  phenotypes. *Nat. Genet.* 53, 1415–1424 (2021).
- 59. The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
   human tissues. *Science* 369, 1318–1330 (2020).
- 1002 60. Kerimov, N. *et al.* A compendium of uniformly processed human gene expression and splicing quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).
- 100461. Koskela, J. T. *et al.* Genetic variant in SPDL1 reveals novel mechanism linking pulmonary1005fibrosis risk and cancer protection. *bioRxiv* (2021) doi:10.1101/2021.05.07.21255988.
- Partanen, J. J. *et al.* Leveraging global multi-ancestry meta-analysis in the study of
   Idiopathic Pulmonary Fibrosis genetics. *bioRxiv* (2021) doi:10.1101/2021.12.29.21268310.
- 1008 63. Foreman, M. G. *et al.* Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic
  1009 Obstructive Pulmonary Disease in Two Racial Groups. *Ann. Am. Thorac. Soc.* 14, 1280–
  1010 1287 (2017).
- 1011 64. Tsuo, K. *et al.* Multi-ancestry meta-analysis of asthma identifies novel associations and highlights the value of increased power and diversity. *bioRxiv* (2021) doi:10.1101/2021.11.30.21267108.
- 1014 65. Benonisdottir, S. *et al.* Epigenetic and genetic components of height regulation. *Nat.* 1015 *Commun.* 7, 13490 (2016).
- 1016 66. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature*1017 542, 186–190 (2017).
- 1018 67. Langefeld, C. D. *et al.* Transancestral mapping and genetic load in systemic lupus
  1019 erythematosus. *Nat. Commun.* 8, 16021 (2017).

- 1020 68. Hargreaves, C. E. *et al.* Fcγ receptors: genetic variation, function, and disease. *Immunol.* 1021 *Rev.* 268, 6–24 (2015).
- Franke, L. *et al.* Association analysis of copy numbers of FC-gamma receptor genes for
  rheumatoid arthritis and other immune-mediated phenotypes. *Eur. J. Hum. Genet.* 24, 263–
  270 (2016).
- 1025 70. UK10K Consortium *et al.* The UK10K project identifies rare variants in health and disease.
   1026 Nature 526, 82–90 (2015).
- 1027 71. Wang, Y. *et al.* Global biobank analyses provide lessons for computing polygenic risk
   scores across diverse cohorts. *medRxiv* 2021.11.18.21266545 (2021).
- 1029 72. Namba, S. *et al.* A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. *bioRxiv* (2021) doi:10.1101/2021.12.03.21267280.
- 1031 73. Wu, K.-H. H. *et al.* Polygenic risk score from a multi-ancestry GWAS uncovers susceptibility 1032 of heart failure. *bioRxiv* (2021) doi:10.1101/2021.12.06.21267389.
- 1033 74. Lo Faro, V. *et al.* Genome-wide association meta-analysis identifies novel ancestry-specific
  1034 primary open-angle glaucoma loci and shared biology with vascular mechanisms and cell
  1035 proliferation. *bioRxiv* (2021) doi:10.1101/2021.12.16.21267891.
- 1036 75. Surakka, I. *et al.* Multi-ancestry meta-analysis identifies 2 novel loci associated with
  ischemic stroke and reveals heterogeneity of effects between sexes and ancestries. *bioRxiv* (2022) doi:10.1101/2022.02.28.22271647.
- 1039 76. Wolford, B. N. *et al.* Multi-ancestry GWAS for venous thromboembolism identifies novel loci
  1040 followed by experimental validation in zebrafish. *medRxiv* (2022)
  1041 doi:10.1101/2022.06.21.22276721.
- 1042 77. Aneas, I. *et al.* Asthma-associated genetic variants induce IL33 differential expression
  1043 through an enhancer-blocking regulatory region. *Nat. Commun.* **12**, 6115 (2021).
- 1044
  78. Vladich, F. D. *et al.* IL-13 R130Q, a common variant associated with allergy and asthma,
  1045
  1046
  115, 747–754 (2005).
- 1047 79. All of Us Research Program Investigators *et al.* The 'All of Us' Research Program. *N. Engl.*1048 *J. Med.* 381, 668–676 (2019).
- 1049 80. Farh, K. K.-H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* 518, 337–343 (2015).
- 1051 81. Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for complex
   1052 traits. *Nature* 570, 514–518 (2019).
- 1053 82. Luo, Y. *et al.* A high-resolution HLA reference panel capturing global population diversity
  1054 enables multi-ancestry fine-mapping in HIV host response. *Nat. Genet.* 53, 1504–1516
  1055 (2021).
- 1056 83. Sakaue, S. *et al.* Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method. *Cell Genomics* 2, (2022).
- 1058 84. Mukamel, R. E. *et al.* Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. *Science* **373**, 1499–1505 (2021).
- 1060 85. Mägi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies
  1061 accounting for ancestry increases power for discovery and improves fine-mapping
  1062 resolution. *Hum. Mol. Genet.* 26, 3639–3650 (2017).
- 1063 86. Gagliano Taliun, S. A. *et al.* Exploring and visualizing large-scale genetic associations by using PheWeb. *Nat. Genet.* 52, 550–552 (2020).
- 1065 87. Su, Ž., Marchini, J. & Donnelly, P. HAPGEN2: Simulation of multiple disease SNPs.
  1066 *Bioinformatics* 27, 2304–2305 (2011).
- 1067 88. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
   1068 *Bioinformatics* 26, 2867–2873 (2010).
- 1069 89. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4, 7 (2015).

- 1071 90. Wei, X. & Nielsen, R. CCR5- $\Delta$ 32 is deleterious in the homozygous state in humans. *Nat.* 1072 *Med.* **25**, 909–910 (2019).
- 1073 91. Maier, R. *et al.* No statistical evidence for an effect of CCR5-∆32 on lifespan in the UK
  1074 Biobank cohort. *Nat. Med.* 26, 178–180 (2020).
- 1075 92. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1076 1284–1287 (2016).
- 1077 93. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat. Genet.* 48, 1443–1448 (2016).
- 1079 94. Loh, P.-R. *et al.* Contrasting genetic architectures of schizophrenia and other complex
- 1080 diseases using fast variance-components analysis. *Nat. Genet.* **47**, 1385–1392 (2015).
- 1081 95. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

#### 1083 Global Biobank Meta-analysis Initiative

1084 Wei Zhou<sup>1,2,3</sup>, Masahiro Kanai<sup>1,2,3,4,5</sup>, Kuan-Han H Wu<sup>6</sup>, Humaira Rasheed<sup>7,8,9</sup>, Kristin Tsuo<sup>1,2,3</sup>, Jibril B Hirbo<sup>10,11</sup>, Ying Wang<sup>1,2,3</sup>, Arjun Bhattacharya<sup>12</sup>, Huiling Zhao<sup>9</sup>, Shinichi Namba<sup>5</sup>, Ida Surakka<sup>13</sup>, Brooke N Wolford<sup>6,7</sup>, Valeria Lo Faro<sup>14,15,16</sup>, Esteban A Lopera-Maya<sup>17</sup>, Kristi Läll<sup>18</sup>, 1085 1086 Marie-Julie Favé<sup>19</sup>, Juulia J Partanen<sup>20</sup>, Sinéad B Chapman<sup>2,3</sup>, Juha Karjalainen<sup>1,2,3,20</sup>, Mitja 1087 Kurki<sup>1,2,3,20</sup>, Mutaamba Maasha<sup>1,2,3,20</sup>, Ben M Brumpton<sup>7,21,22</sup>, Sameer Chavan<sup>23</sup>, Tzu-Ting Chen<sup>24</sup>, 1088 Michelle Daya<sup>23</sup>, Yi Ding<sup>25,12</sup>, Yen-Chen A Feng<sup>26</sup>, Lindsay A Guare<sup>27</sup>, Christopher R Gignoux<sup>23</sup>, 1089 Sarah E Graham<sup>13</sup>, Whitney E Hornsby<sup>13</sup>, Nathan Ingold<sup>28,29</sup>, Said I. Ismail<sup>30</sup>, Ruth Johnson<sup>31,12</sup>, 1090 Triin Laisk<sup>18</sup>, Kuang Lin<sup>32</sup>, Jun Lv<sup>33</sup>, Iona Y Millwood<sup>32,34</sup>, Sonia Moreno-Grau<sup>35</sup>, Kisung Nam<sup>36</sup>, 1091 Triin Laisk<sup>18</sup>, Kuang Lin<sup>32</sup>, Jun Lv<sup>33</sup>, Iona Y Millwood<sup>32,34</sup>, Sonia Moreno-Grau<sup>35</sup>, Kisung Nam<sup>36</sup>, Priit Palta<sup>18,20</sup>, Anita Pandit<sup>37</sup>, Michael H Preuss<sup>38</sup>, Chadi Saad<sup>30</sup>, Shefali S Setia<sup>39</sup>, Unnur Thorsteinsdottir<sup>40</sup>, Jasmina Uzunovic<sup>19</sup>, Anurag Verma<sup>41,42</sup>, Matthew Zawistowski<sup>37</sup>, Xue Zhong<sup>10,11</sup>, Nahla Afifi<sup>43</sup>, Kawthar M. Al-Dabhani<sup>43</sup>, Asma Al Thani<sup>43</sup>, Yuki Bradford<sup>27</sup>, Archie Campbell<sup>44</sup>, Kristy Crooks<sup>23</sup>, Geertruida H de Bock<sup>45</sup>, Scott M Damrauer<sup>46,27,42</sup>, Nicholas J Douville<sup>47,48</sup>, Sarah Finer<sup>49</sup>, Lars G Fritsche<sup>37</sup>, Eleni Fthenou<sup>43</sup>, Gilberto Gonzalez-Arroyo<sup>35,50</sup>, Christopher J Griffiths<sup>49</sup>, Yu Guo<sup>51</sup>, Karen A Hunt<sup>52</sup>, Alexander Ioannidis<sup>35,53</sup>, Nomdo M Jansonius<sup>14</sup>, Takahiro Konuma<sup>5,54</sup>, Ming Ta Michael Lee<sup>35</sup>, Arturo Lopez-Pineda<sup>35,50</sup>, Yuta Matsuda<sup>55</sup>, Riccardo E Marioni<sup>44</sup>, Babak Moatamed<sup>35</sup>, Marco A Nava-Aguilar<sup>35,50</sup>, Kensuke Numakura<sup>55</sup>, Snebal Patil<sup>37</sup>, Nicholas Rafaels<sup>23</sup>, Anne Richmond<sup>56</sup>, Agustin Rojas-Muñoz<sup>35</sup> 1092 1093 1094 1095 1096 1097 1098 1099 Numakura<sup>55</sup>, Snehal Patil<sup>37</sup>, Nicholas Rafaels<sup>23</sup>, Anne Richmond<sup>56</sup>, Agustin Rojas-Muñoz<sup>35</sup>, Jonathan A Shortt<sup>23</sup>, Peter Straub<sup>10,11</sup>, Ran Tao<sup>57,11</sup>, Brett Vanderwerff<sup>37</sup>, Manvi Vernekar<sup>55</sup>, 1100 1101 Yogasudha Veturi<sup>27</sup>, Kathleen C Barnes<sup>23</sup>, Marike Boezen<sup>45</sup>‡, Zhengming Chen<sup>32,34</sup>, Chia-Yen Chen<sup>58</sup>, Judy Cho<sup>38</sup>, George Davey Smith<sup>9,59</sup>, Hilary K Finucane<sup>1,3,2</sup>, Lude Franke<sup>17</sup>, Eric R Gamazon<sup>10,11,60</sup>, Andrea Ganna<sup>1,2,20</sup>, Tom R Gaunt<sup>9,59</sup>, Tian Ge<sup>61,62</sup>, Hailiang Huang<sup>1,2</sup>, Jennifer 1102 1103 1104 Huffman<sup>63</sup>, Nicholas Katsanis<sup>35</sup>, Jukka T Koskela<sup>20</sup>, Clara Lajonchere<sup>64,65</sup>, Matthew H Law<sup>28,29</sup>, Liming Li<sup>33</sup>, Cecilia M Lindgren<sup>66</sup>, Ruth JF Loos<sup>38,67</sup>, Stuart MacGregor<sup>28</sup>, Koichi Matsuda<sup>68</sup>, 1105 1106 Catherine M Olsen<sup>28</sup>, David J Porteous<sup>44</sup>, Jordan A Shavit<sup>69</sup>, Harold Snieder<sup>45</sup>, Tomohiro Takano<sup>55</sup>, Richard C Trembath<sup>70</sup>, Judith M Vonk<sup>45</sup>, David C. Whiteman<sup>28</sup>, Stephen J Wicks<sup>23</sup>, 1107 1108 Cisca Wijmenga<sup>17</sup>, John Wright<sup>71</sup>, Jie Zheng<sup>9</sup>, Xiang Zhou<sup>37</sup>, Philip Awadalla<sup>19,72</sup>, Michael Boehnke<sup>37</sup>, Carlos D Bustamante<sup>35,53,73</sup>, Nancy J Cox<sup>10,11</sup>, Segun Fatumo<sup>74,75,76</sup>, Daniel H 1109 1110 Geschwind<sup>77,64,78</sup>, Caroline Hayward<sup>56</sup>, Kristian Hveem<sup>7,21</sup>, Eimear E Kenny<sup>79</sup>, Seunggeun Lee<sup>36</sup>, 1111 Yen-Feng Lin<sup>24,80,81</sup>, Hamdi Mbarek<sup>30</sup>, Reedik Mägi<sup>18</sup>, Hilary C Martin<sup>82</sup>, Sarah E Medland<sup>28</sup>, Yukinori Okada<sup>5,83,84,85,86</sup>, Aarno V Palotie<sup>1,2,20</sup>, Bogdan Pasaniuc<sup>12,77,87,25,64</sup>, Daniel J Rader<sup>27,41</sup>, 1112 1113 Marylyn D Ritchie<sup>27</sup>, Serena Sanna<sup>88,17</sup>, Jordan W Smoller<sup>61</sup>, Kari Stefansson<sup>40</sup>, David A van Heel<sup>52</sup>, Robin G Walters<sup>32,34</sup>, Sebastian Zöllner<sup>37</sup>, Biobank of the Americas, Biobank Japan 1114 1115 1116 Project, BioMe, BioVU, CanPath - Ontario Health Study, China Kadoorie Biobank Collaborative 1117 Group, Colorado Center for Personalized Medicine, deCODE Genetics, Estonian Biobank, 1118 FinnGen, Generation Scotland, Genes & Health Research Team, LifeLines, Mass General 1119 Brigham Biobank, Michigan Genomics Initiative, National Biobank of Korea, Penn Medicine 1120 BioBank, Qatar Biobank, The QSkin Sun and Health Study, Taiwan Biobank, The HUNT Study, 1121 UCLA ATLAS Community Health Initiative, Uganda Genome Resource, UK Biobank, Alicia R Martin<sup>1,2,3</sup>, Cristen J Willer<sup>13,6,89\*</sup>, Mark J Daly<sup>1,2,3,20\*</sup>, Benjamin M Neale<sup>1,2,3\*</sup> 1122

- 1123
- 1124 ‡Deceased
- 1125 \*These authors jointly supervised the initiative
- 1126

<sup>1</sup>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General
 Hospital, Boston, MA, USA, <sup>2</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and
 Harvard, Cambridge, MA, USA, <sup>3</sup>Program in Medical and Population Genetics, Broad Institute of

MIT and Harvard, Cambridge, MA, USA, <sup>4</sup>Department of Biomedical Informatics, Harvard Medical 1130 School, Boston, MA, USA, <sup>5</sup>Department of Statistical Genetics, Osaka University Graduate 1131 1132 School of Medicine, Suita 565-0871, Japan, <sup>6</sup>Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA, <sup>7</sup>K.G. Jebsen Center for Genetic 1133 Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science 1134 and Technology, Trondheim, Norway, <sup>8</sup>Division of Medicine and Laboratory Sciences, University 1135 1136 of Oslo, Norway, <sup>9</sup>MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of 1137 Bristol, Bristol, UK, <sup>10</sup>Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, <sup>11</sup>Vanderbilt Genetics Institute, Vanderbilt University Medical 1138 Center, Nashville, TN, USA, <sup>12</sup>Department of Pathology and Laboratory Medicine, David Geffen 1139 1140 School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, <sup>13</sup>Department 1141 of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, USA, 1142 <sup>14</sup>University of Groningen, UMCG, Department of Ophthalmology, Groningen, the Netherlands, 1143 <sup>15</sup>Department of Clinical Genetics, Amsterdam University Medical Center (AMC), Amsterdam, the 1144 Netherlands, <sup>16</sup>Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, <sup>17</sup>University of Groningen, UMCG, Department of Genetics, Groningen, the Netherlands, <sup>18</sup>Estonian Genome Centre, Institute of Genomics, 1145 1146 University of Tartu, Tartu, Estonia, <sup>19</sup>Ontario Institute for Cancer Research, Toronto, ON, Canada, 1147 <sup>20</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, <sup>21</sup>HUNT 1148 1149 Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway, <sup>22</sup>Clinic of Medicine, St. Olavs Hospital, Trondheim 1150 University Hospital, Trondheim, Norway, <sup>23</sup>University of Colorado - Anschutz Medical Campus, 1151 1152 Aurora, CO, USA, <sup>24</sup>Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan, <sup>25</sup>Bioinformatics Interdepartmental Program, University of California, Los Angeles, 1153 Los Angeles, CA, USA, <sup>26</sup>Division of Biostatistics, Institute of Epidemiology and Preventive 1154 Medicine, College of Public Health, National Taiwan University, Taiwan, <sup>27</sup>Department of 1155 1156 Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 1157 <sup>28</sup>QIMR Berghofer Medical Research Institute, Brisbane, Australia, <sup>29</sup>Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Australia, <sup>30</sup>Qatar Genome Program, 1158 Qatar Foundation Research, Development and Innovation, Qatar Foundation, Doha, Qatar, 1159 1160 <sup>31</sup>Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, USA, <sup>32</sup>Nuffield Department of Population Health, University of Oxford, Oxford, UK, <sup>33</sup>Department of 1161 Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 1162 1163 Beijing, China, <sup>34</sup>MRC Population Health Research Unit, University of Oxford, Oxford, UK, <sup>35</sup>Galatea Bio Inc., Hialeah, FL, USA, <sup>36</sup>Graduate School of Data Science, Seoul National 1164 1165 University, <sup>37</sup>Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA, <sup>38</sup>The Charles Bronfman Institute for Personalized Medicine, Icahn 1166 School of Medicine at Mount Sinai, New York, NY, USA, <sup>39</sup>Department of Pathology and 1167 Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 1168 1169 USA, <sup>40</sup>deCODE Genetics/Amgen inc., 101, Reykjavik, Iceland, <sup>41</sup>Department of Medicine, 1170 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, <sup>42</sup>Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA, <sup>43</sup>Qatar Biobank for Medical 1171 Research, Qatar Foundation for Education, Science, and Community, Doha, Qatar, <sup>44</sup>Centre for 1172 Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, 1173 Edinburgh, UK, <sup>45</sup>Department of Epidemiology, University Medical Center Groningen, Groningen, 1174 the Netherlands, <sup>46</sup>Department of Surgery, Perelman School of Medicine, University of 1175 Pennsylvania, Philadelphia, PA, USA, <sup>47</sup>Department of Anesthesiology, Michigan Medicine, Ann 1176 Arbor, MI, USA, <sup>48</sup>Institute of Healthcare Policy & Innovation, University of Michigan, Ann Arbor, 1177 MI, USA, <sup>49</sup>Wolfson Institute of Population Health, Queen Mary University of London, London, 1178 1179 UK, <sup>50</sup>Amphora Health, Morelia, Michoacan, Mexico, <sup>51</sup>Chinese Academy of Medical Sciences, 1180 Beijing, China, <sup>52</sup>Blizard Institute, Queen Mary University of London, London, UK, <sup>53</sup>Stanford

University School of Medicine, Stanford, CA, USA, <sup>54</sup>Central Pharmaceutical Research Institute, 1181 JAPAN TOBACCO INC., Takatsuki 569-1125, Japan, <sup>55</sup>Genomelink, Inc., Berkeley, CA, USA, 1182 1183 <sup>56</sup>Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, <sup>57</sup>Department of Biostatistics, Vanderbilt University Medical Center, 1184 Nashville, TN, USA, <sup>58</sup>Biogen, Cambridge, MA, USA, <sup>59</sup>NIHR Bristol Biomedical Research Centre, 1185 Bristol, UK, <sup>60</sup>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK, <sup>61</sup>Psychiatric 1186 1187 and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General 1188 Hospital, Boston, MA, USA, <sup>62</sup>Center for Precision Psychiatry, Massachusetts General Hospital, Boston, MA, USA, <sup>63</sup>Centre for Population Genomics, VA Boston Healthcare System, Boston, 1189 1190 MA, USA, <sup>64</sup>Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. <sup>65</sup>Program in Neurogenetics. Department of Neurology. David Geffen School of Medicine. 1191 1192 University of California, Los Angeles, Los Angeles, CA, USA, <sup>66</sup>Big Data Institute, Li Ka Shing 1193 Centre for Health Information and Discovery, University of Oxford, Oxford, UK, <sup>67</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Medicine and Health Sciences, 1194 University of Copenhagen, Copenhagen, Denmark, <sup>68</sup>Department of Computational Biology and 1195 1196 Medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo, Tokyo, Japan, 1197 <sup>69</sup>University of Michigan, Department of Pediatrics, Ann Arbor MI 48109, <sup>70</sup>School of Basic and 1198 Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK, 1199 <sup>71</sup>Bradford Institute for Health Research, Bradford Teaching Hospitals National Health Service 1200 (NHS) Foundation Trust, Bradford, UK, <sup>72</sup>Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, <sup>73</sup>Chan Zuckerberg Biohub, San Francisco, CA, USA, <sup>74</sup>The 1201 1202 African Computational Genomics (TACG) Research Group, MRC/UVRI and LSHTM, Entebbe, 1203 Uganda, <sup>75</sup>London School of Hygiene & Tropical Medicine London, UK, <sup>76</sup>Medical Research Council/ Uganda Virus Research Institute/London School of Hygiene and Tropical Medicine 1204 (MRC/UVRI/LSHTM) Uganda research unit, Entebbe, Uganda, <sup>77</sup>Department of Human Genetics, 1205 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, 1206 1207 <sup>78</sup>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, <sup>79</sup>Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA, <sup>80</sup>Department of Public Health & Medical Humanities, School 1208 1209 of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, <sup>81</sup>Institute of Behavioral 1210 1211 Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, <sup>82</sup>Medical and Population Genomics, Wellcome Sanger Institute, Hinxton, UK, <sup>83</sup>Department of Genome 1212 Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo 113-0033, Japan., 1213 1214 <sup>84</sup>Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita 565-0871, Japan, <sup>85</sup>Laboratory for Systems Genetics, RIKEN Center for 1215 Integrative Medical Sciences, Yokohama, Japan, <sup>86</sup>Integrated Frontier Research for Medical 1216 1217 Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita 565-0871, Japan.<sup>87</sup>Department of Computational Medicine, David Geffen School of 1218 1219 Medicine, University of California, Los Angeles, Los Angeles, CA, USA, <sup>88</sup>Institute for Genetics 1220 and Biomedical Research (IRGB), National Research Council (CNR), Cagliari, Italy, <sup>89</sup>Department 1221 of Human Genetics, University of Michigan, Ann Arbor, MI, USA

- 1222
- 1223 1224